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1. Baseline State of the Health Care Sector 
 
This scenario report considers the pathways that health biotechnologies could follow, the future 
trajectory of the bioeconomy primarily in the context of human health1 and the likely societal, 
economic and policy impacts of these projected outcomes, focusing on the period 2012/15 to 2030.  
 
The impact of biotechnologies on health care has so far primarily operated through the development of 
drugs, either in the development of new types of molecules, in contributions to discovery, or to safety 
and efficacy evaluation. The starting point for development of our scenarios is thus a world health care 
system that, from the perspective of potential impacts of biotechnology, has been dominated by the 
innovation model of the multinational drug companies. The current economic climate for this sector is 
one where increasing competition has led to waves of mergers and acquisitions, leading to an ever-
increasing scale of operations for multinational companies alongside the parallel trend increasingly to 
out-source activities related to drug discovery and development.2,3 
 
Our scenarios consider the future of the bioeconomy to 2030 particularly from the perspectives of the 
following four constituencies, their interactions with one another and with the relevant trends 
described in the OECD’s Baseline Assumptions about Long Term Global Trends Shaping the 
Development of the Bioeconomy. Across these four constituencies, some are organised systemically 
and some are not, and they also show varying degrees of international organisation. We use the 
following terminology throughout this report to identify the focus of attention at any particular point. 
We also use the term “health care sector” to refer to the sometimes rather chaotic and poorly organised 
arrangement of all these components as they contribute to public health in general. 
 
 The global science and industry innovation system includes public sector organisations 
involved in basic discovery and in offering supporting services to the commercial sector (for 
example in conducting clinical trials) and also commercial companies, ranging from small and 
medium sized enterprises (SMEs) to some of the biggest multinational companies (MNCs).  
 The increasingly global regulatory system where convergence of national regulatory systems, 
particularly those of the United States and the European Union, can be expected to be much 
more closely aligned by 2015. 
 National health care delivery systems which cannot currently be regarded as internationally 
organised. For example the American health system differs dramatically from those of most 
European countries and health care systems in the south are very different from those in the 
north, with little evidence to suggest that they will begin to converge globally, rather than 
diverging in the foreseeable future. 
                                                 
1 We also consider animal health-related influences insofar as they are relevant to the overall evolution of the 
health bioeconomy. Given that health care products for animals constitute approximately 3% of the profit 
base of pharmaceutical companies, with a similarly low contribution to the bioeconomy as a whole (OECD 
data), developments in animal health care are unlikely to be major drivers of change in this sector. However, 
in the longer term concerns and opportunities arising in animal health care may have a more major influence 
on innovation in health care as a whole and also zoonoses, exacerbated by climate change, may change the 
focus of public and commercial funding for health-related innovation (See Box 3). 
2 Mittra, J. (2007), “Life Science Innovation and the Restructuring of the Pharmaceutical Industry: Merger, 
Acquisition and Strategic Alliance Behaviour of Large Firms,” Technology Analysis and Strategic 
Management, 19(3), pp. 279-301.  
3 Rafferty M.A, (2007), “Managing Change in Biotech: Mergers and Acquisitions,” Nature Biotechnology, 
25(6), pp. 489-490. 
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 The fourth constituency in this analysis includes stakeholder and advocacy groups who, with 
varying degrees of legitimacy, claim to represent public or patient interests related to health 
care delivery. Some individual groups may operate on a global basis, but these groups are not 
yet organised systemically. Our scenarios will consider the circumstances under which a 
systemically organised advocacy coalition may arise which could have an impact on the future 
of the bioeconomy.4 
 
Our scenario analyses are organised around the above four constituencies, along with the other key 
drivers of change identified by the OECD that are considered relevant to the health care sector – 
global economics, demography and human resources, climate change, security and developments in 
animal health, as outlined in Section 2. 
 
Biotechnology innovation has already had a major influence on drug development. It has contributed 
to improving drug-related R&D processes and also to the development of new biotechnology-based 
drug molecules. SMEs with strong biotechnology-based drug pipelines have become a target for 
MNCs seeking to acquire these products to supplement their own flagging pipelines.5,6 With a few 
early exceptions from the 1980s, such as Genentech (until recently) and Amgen, SMEs have not been 
able to challenge the market dominance of the MNCs. Those companies that have managed to grow 
and at the same time to remain relatively independent have flourished by forging close links with 
traditional pharmaceutical companies rather than by attempting to compete on the basis of a new 
innovation model. 
 
In contrast to the health-care industries, over the past thirty years, the information and communication 
technology (ICT) sector has been repeatedly shaken up by new R&D models and new types of 
products, for example personal computers or mobile phones as hardware developments, and software-
related developments by Microsoft and Google. These have, over a short space of time, transformed 
existing markets and created new ones, and also changed the sectoral landscape beyond recognition. 
Very large multinational companies have had to change their R&D models (e.g. IBM) or have greatly 
diminished in size and influence or disappeared altogether, while new companies have generated huge 
fortunes for their owners and shareholders. Innovation in the ICT sector has thus created a relatively 
rapid rate of “churn” in company and technology dominance so that the sector today bears very little 
comparison to the one that existed in the 1970s.7 
 
In the 1980s, biotechnology was expected to have a similar impact on health care industries and, while 
it has indeed played an important role in their development, this has been mainly supportive of the 
prevailing model for drug discovery, rather than challenging it.  Despite large scale public and private 
investment, the sector is still dominated by a similar set of companies (although their names may have 
changed) and the basic innovation model remains fundamentally unaltered.8 
 
The most important factor contributing to this long term resilience of the drug-based innovation 
model, and its dominant role in the development of health care systems, is the regulatory system. The 
                                                 
4  Tait J., (2001), More Faust than Frankenstein: the European Debate about Risk Regulation for Genetically 
Modified Crops. Journal of Risk Research, 4(2), pp. 175-189. This paper explains how such an advocacy 
coalition arose around the development of GM crops and how it was able to change the development 
trajectory of this technology. 
5  Anon., (2007), “News in Brief: AstraZeneca to Acquire Medimmune in Multi-billion Dollar Deal” Nature 
Reviews, 6, p. 424. 
6  Kling J., (2006), “Merck Moves into Biotech”, Nature Biotechnology, 24(7), p. 730. 
7  Tait J. and Williams, R. (1999), Policy Approaches to Research and Development: Foresight, Framework and 
Competitiveness. Science and Public Policy, 26(2), pp. 101-112. 
8  Tait J., (2007), Systemic Interactions in Life Science Innovation. Technology Analysis and Strategic 
Management, 19(3), pp. 257-277, May 2007. 
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European and United States regulatory systems impose very significant constraints on the innovation 
system for drugs and many other health care products through the lengthy, expensive and complex sets 
of regulatory requirements that need to be met to bring a product to the market. In drug development, 
this regulatory barrier to entry is a largely ignored, but important factor in giving multinational 
companies their dominant role over innovative technology in health care. For example, Thomas has 
shown that smaller United States pharmaceutical firms suffered a devastating reduction in research 
productivity as a result of the US Food and Drugs Administration (FDA) adoption of the 1962 
Kefauver amendments to the 1938 Food, Drug and Cosmetic Act while the largest United States firms 
benefited from regulation in that sales gains due to reduced competition more than offset their modest 
declines in productivity.9 Formal regulation is also becoming an increasingly important factor in areas 
of health care that used to receive a much lighter regulatory touch, for example diagnostics and tissue-
based therapies. This is having similar effects on the ability of small companies to operate profitably, 
and also the ability and willingness of all companies to respond rapidly to new ideas and scientific 
discoveries, particularly those that do not have a good “fit” with current regulatory systems. 
 
Robert Powell has also pointed to the basic resilience of the drug development model over the past 40 
years (although there have been major changes in discovery and marketing processes), and also to the 
co-dependency between industry and regulators as a source of resistance to change.10 He observed that 
conservatism and the need for predictability in how decisions are made influence the dynamics of the 
relationships between the FDA and industry and that it is unlikely that industry will make changes in 
drug development unless the FDA also changes. 
 
The long term resilience of this dominant pharmaceutical innovation model is now increasingly being 
questioned. The health care sector has become mature in the sense that treatments have been 
developed for all the easy targets and these products are now off-patent commodities no longer 
attracting high profit margins. It has become increasingly difficult to find new products that are 
effective enough to compete with existing product ranges, safe enough to pass the regulatory systems, 
and cheap enough to manufacture, hence the “drying up” of product pipelines.  
 
Such problems in the pharmaceutical industry led analysts to expect a period of “creative destruction”, 
as has been the case for the ICT sector, where small start-up companies with a range of different 
innovation models challenge the status quo and develop products for new or un-met needs in health 
care or revolutionise current treatments. However, the structure of the pharmaceutical innovation 
sector has resisted fundamental change despite the injection of a range of potentially revolutionary 
biotechnologies. Biotechnology innovations have been absorbed into the industry sector and indeed 
have served to support its current structure, rather than undermining it. The structure of the science 
and industry innovation system, closely coupled to a complex interacting set of markets and regulatory 
systems has served public health care needs in the developed world reasonably well for the last fifty 
years. However, under challenge from an increasingly complex range of innovative biotechnologies 
(including for example stem cells and pharmacogenetics), it is beginning to appear increasingly 
sclerotic, to the extent that we can no longer imagine alternative futures.  
 
Thus fundamental, rather than incremental, change becomes increasingly inevitable, but also 
increasingly unimaginable. Some time in the future, the science and industry innovation system may 
experience a “Black Swan”,11 but according to Taleb, the nature and timing of the stimuli are, by 
                                                 
9  Thomas L.G., “Regulation and Firm Size: FDA Impacts on Innovation”, RAND Journal of Economics, 21(4), 
1990, pp. 497-517. 
10  Robert Powell, FDA Office of Translational Sciences, Centre for Drug Evaluation and Research (CDER), 
2007. Presentation to Innogen Executive Development Programme, 25th-27th April, 2007, Edinburgh, 
Scotland. 
11  Taleb N.N., (2007), The Black Swan: the impact of the highly improbable. London: Allen Lane. A “Black 
Swan” has the following attributes: it is an outlier; it carries an extreme impact; and it appears explainable 
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definition, unpredictable. Contrary to Taleb’s view, one role of scenarios is to imagine the 
unimaginable and then to devise means to prevent catastrophe, to cope with fundamental change or, as 
in the second scenario in this report, to engineer fundamental change. Successful, positive engineering 
of fundamental change often requires the coming together of two or more visionary individuals who, 
perhaps because of unfamiliarity with the existing context, a lack of understanding of “What can’t be 
done” can imagine alternative futures and also have the necessary skills to make them happen. 
 
Incremental change, as discussed in the first scenario, can be the norm for a considerable period of 
time, with simultaneous changes taking place in science and innovation systems, regulatory systems, 
health care delivery systems, and stakeholder and advocacy groups. Each individual change will add to 
or (occasionally) subtract from the overall pressure for change, building up over time a log-jam that 
becomes increasingly unstable. Once the instability has reached a certain level, it only takes one small, 
apparently insignificant change, the removal of a single log, to break up the log jam in a process that 
can be chaotic and destructive. 
 
The first scenario in this report describes the continuation of the current series of incremental changes 
through to 2030, with increasing build-up of pressure for change and increasing “instability of the log-
jam”. The second scenario describes the situation where, some time between 2015 and 2030, a 
combination of visionary individuals with the financial backing and the ability to engineer 
fundamental change, supported by a range of appropriate incremental changes in the components of 
the health care sector, is able to engineer a relatively rapid and non-destructive transition to a new, 
transformed science and industry innovation system. 
 
The future of the health bioeconomy by 2030 thus will be determined by the interactions between the 
global science and industry innovation system, the increasingly global regulatory system, the 
increasingly divergent range of national and regional health care delivery systems and the stakeholder 
and advocacy groups that so far have not become systemically organised. 
 
The changes in the bioeconomy beyond 2012 will each appear disruptive to some of the major players 
in such a complex context. However, we distinguish our two scenarios on the basis of the skill and 
adaptability with which change is managed by two of the key constituencies in the health bioeconomy, 
the science and industry innovation system and the regulatory system. Also, although industry and 
regulators will need to be the lead agents in such changes, the health care delivery systems and those 
who pay for health care will also need to act as intelligent consumers of innovative health care in the 
new bioeconomy. 
 
The first scenario, Muddling through, envisages the outcome where there is resistance to change in the 
healthcare sector, and the key constituencies outlined above are unable to align their interests resulting 
in a competitive environment that is not conducive to rapid and creative biotechnology innovation, 
accompanied by sporadic, localised conflicts. 
 
The second scenario Rapid Change will require a fortuitous sequence of changes to innovation and 
regulatory systems resulting in significant changes to society and the economy. This will require a 
willingness of industry, regulators and stakeholder groups to collaborate in ensuring a smooth 
transition to a set of overall healthcare systems that deliver a more equitable distribution of benefits 
and a more cost-effective translation of innovative developments “from bench to bedside”.  
 
The changes envisaged will help shape social and economic transformations, not just in the science 
and industry innovation subsystem, but also in the labour-intensive health care sectors, with the need 
                                                                                                                                                        
and predictable after the event. Taleb’s examples include the emergence of the internet, the 9/11 disaster, the 
sinking of the Titanic, the United States banking crisis of 1982. 
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for changes in professional training, for example to deliver personalised medicines. The challenges to 
traditional medical vested interests presented by biotechnology-related innovations will also need to be 
managed carefully to achieve the outcome envisaged in the first scenario. 
 
While we cannot predict or direct the outcomes of changes in complex interacting systems such as 
those involved in the health care sector over long periods of time, we can ensure that policy and 
regulatory actions are taken with the best available knowledge of how they are likely to determine or 
influence the future direction of change. 
 
2. Drivers of Change to 2030 
 
The following drivers of change, including those specified by OECD12 are considered likely to 
contribute to the post-2012 health care scenarios.  
 
Exogenous drivers envisaged by OECD are those which do not directly influence the biotechnology 
sector, for example climate change impacts and general global economic developments.  
 
Endogenous factors include those that are directly related to developments or decisions within the 
health care sector, such as government policy, new developments in health care delivery systems, 
public and stakeholder attitudes, new business models, new funding models, new innovative 
developments, i.e. those relevant to the sub-systems and groups described above. The most important 
contributions to the future of the bioeconomy are expected to arise from biotechnology innovation and 
research, policy and regulatory changes, changes in health care delivery systems, and stakeholder and 
advocacy group attitudes.  
 
Demographic change partly endogenous and partly exogenous, being driven by many factors out with 
the bioeconomy as well as being directly affected by it. 
 
However, in all cases, the scenarios that emerge in future will be determined by interactions among 
exogenous and endogenous drivers, emphasising the importance of the timing of future developments. 
Synchronous change in two key drivers could have major implications for future health care systems, 
whereas if the same two developments are separated by a period of years, their impacts could be 
barely noticeable. On the other hand future developments that take place almost consecutively could 
cancel one another out whereas if they occur over a period of years they may have a powerful 
influence on the shape of the bioeconomy. These issues are discussed in more detail in 
Sections 4 and 5. 
 
2.1 Technology and Research (the science and industry innovation 
system) 
Research in the biosciences, publicly and privately (including both commercially and charitably) 
funded, and technological innovations that emerge from this research, are likely to be the main 
determinants of future healthcare scenarios. Investment in bioscience and biotechnology is currently 
high in the developed world and can be expected to increase there and also to become a much more 
important feature in the economies of the new rapidly developing economies.  
National governments are likely to continue to invest in fundamental discovery in this sector, partly 
because it is seen to be an important component of a country’s international competitive position. 
There is also an increasing trend for governments to invest in “translational research”, to take products 
                                                 
12  OECD (2007), Baseline Assumptions about Long Term Global Trends Shaping the Development of the 
Bioeconomy. OECD Futures Project on the Bioeconomy to 2030: Designing a Policy Agenda.  
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further along the development route and closer to market application, in an attempt to cover the 
investment gap between the end of basic research funding and demonstration of an investment 
opportunity for the private sector.  
 
Up till now, venture capital has been invested in biotechnology in the expectation of large pay-offs, 
albeit on a long time-scale. The expectation of large pay-offs have mainly not been borne out and 
venture capital investment in biotechnology is faltering, and will probably continue to do so, unless 
there is a fundamental change in the industry innovation system. 
 
Companies in the health care sector can be categorised roughly as (i) large multinationals (“big 
pharma”), (operating globally, with candidate products in all major classes, markets in all major 
countries), (ii) middle-sized multinationals (operating multinationally but not necessarily globally, 
generally focusing on particular niche markets, often partnering with large multinationals to gain 
access to particular markets), (iii) companies of a wide range of sizes, including some divisions of 
large pharmaceutical companies, producing off-patent commodity drugs at relatively low profit 
margins but for larger markets, (iv) small companies developing new drugs with the aim of 
contributing products into the pipelines of the multinationals, either through licensing agreements or 
through takeover, (v) small companies providing analytical and other services to multinational 
companies, (vi) small tissue engineering and diagnostic companies developing products for specific 
niche markets and (so far) remaining relatively independent and profitable enough to permit internally 
generated and sustainable growth. 
 
To an increasing extent these companies, including those developing the most innovative products as 
well as the commodity producers and the service providers, will be based in India and China. 
Although it is not possible to predict the exact nature and timing of future innovations more than a few 
years in advance, it is reasonable to assume that those innovations which survive long enough to be 
influential will have the following types of impact: 
 
 They will enable treatment options to be more targeted to the needs of specific groups of 
patients through more advanced diagnostic tests; 
 They will enable more rapid responses to the emergence of new infectious diseases through 
the development of diagnostic devices, vaccines or antibiotics; 
 They will deliver treatments for currently incurable diseases or for those that are currently 
ignored; 
 They will enable new types of drugs or other treatments to be delivered more effectively or 
more cheaply, for example by speeding their passage through various stages of regulation or 
by developing new approaches to drug delivery or targeting; 
 They will enable complex drug molecules to be synthesised more cheaply; 
 They will enable long term treatments for disease to be replaced by cures; 
 They will allow future susceptibility to disease to be avoided through the use of genetic testing 
and/or dietary supplements. 
 
These technological developments would all be positively enabling from the point of view of 
contributing to better health care systems at the societal level, i.e. they are enabling of the progress of 
the bioeconomy as a whole. However, some of the companies involved in health care will be potential 
winners and some will be potential losers from each type of innovation, i.e. whether a particular 
biotechnology development is enabling or competing will depend on the type of company concerned. 
Companies will be likely to respond variably to each innovation depending on its fit with their current 
innovation models and markets or its potential to contribute to future competitive positions (See Box 
1). For example, stem cells as treatments or cures for long term chronic diseases will not have a good 
fit with the innovation strategies of multinational companies developing new drugs whereas they will 
fit well with the strategies of smaller tissue-engineering based companies developing therapies and 
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potential cures for chronic and currently incurable diseases. On the other hand stem cell related 
developments designed to speed up efficacy and toxicity testing for new pharmaceutical developments 
will fit well with multinational pharmaceutical company strategies.13  
 
Box 1 - Path Breaking and Path Dependent Innovation Systems14 
For more than ten years, analysts have been claiming that, despite a series of life science-based 
innovations, the overall drug discovery and development model of the pharmaceutical industry sector 
is fundamentally unsustainable. Explanations have included failure of innovative capacity, too great a 
focus on incremental rather than radical innovation, excessive regulation, and lack of venture capital 
investment. 
 
However, from an alternative perspective, one could say that the innovation model that has evolved in 
the life science industry sector has been remarkably robust compared, for example to those in 
information and communication technologies. Despite difficulties in markets, the emergence of a 
series of potentially disruptive innovations, the steady build-up of an onerous regulatory system, 
escalating development costs and a product development life span of up to 12 years, the underlying 
business model of the industry sector has remained remarkably constant, and indeed has been 
reinforced, over the past fifty years. The dominance of the multinational corporations (MNCs) and their 
prevailing block-buster drug model of innovation has until recently been unassailable. 
 
Some of the innovative ideas that have emerged from life sciences have been “incremental”, 
presenting few serious challenges to the prevailing innovation model and easily accommodated within 
it. Others are potentially “disruptive”, stepping outside existing paradigms, leading to discontinuities in 
innovation pathways, to major shifts in product types and their place in the market, and even to the 
creation of new industry sectors or radical re-structuring of existing sectors.  
 
Underlying at least some of the public and commercial investment in life sciences has been the 
assumption that the technology in question might be the “next big thing”, the innovation that will lead a 
company to become a multinational in its own right, with a winning strategy that is different from 
incumbent multinationals. More realistic investors assume that they will support a new biotechnology 
firm (NBF) only until it becomes large enough or successful enough to be taken over by, or to license 
its technology to, a multinational. 
 
Barriers to entry 
Regulators impose very significant constraints on life science innovation through the lengthy, 
expensive and complex set of requirements needed to bring a product to the market. This forms a 
barrier to entry for any new firm and is one of the most important factors giving multinational 
companies their dominant role in the sector. A symbiotic relationship has built up between the sectoral 
innovation system and regulatory bodies since the 1950s, with each change in the regulatory 
environment being incorporated into the innovation system in a way that reinforced the dominant 
position of the multinational companies. 
 
Many analyses acknowledge a role for regulation as one factor among many in influencing sectoral 
innovation systems in life sciences. However, we would give it the key, controlling role in explaining 
the long term resilience of the current innovation model of the multinationals. By acting as such an 
effective barrier to entry to the sector it has ensured that, with a few early exceptions, no NBF has 
been able to develop an innovation strategy which challenges or would compete with those of the 
multinational companies. 
 
The market context is also an important, but lesser, barrier to entry to the sector. Unlike most markets, 
products have not generally been sold directly to the public. Despite the increasing volume of internet 
sales, they are still delivered mainly through highly specialist health care networks, publicly or privately 
                                                 
13  See Note 8. 
14  Tait J. (2007), Systemic Interactions in Life Science Innovation. Technology Analysis and Strategic 
Management, 19(3), pp. 257-277, May 2007. 
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funded. As with regulation, it is very difficult for a new entrant to break through this barrier and to 
market its products independently. 
 
Problems of maturity – when is a sector ripe for disruption? 
One factor to be taken into account in charting the future of the life science sector is its maturity, in the 
sense that products have been developed for all the easy targets and these compounds are now off-
patent commodity products no longer attracting high profit margins. It has become increasingly difficult 
to find new products that are effective enough to compete with existing product ranges, safe enough to 
pass the regulatory systems, and cheap enough to manufacture. These factors, and not complacency 
or a failure of innovative capacity, are the main reason for the drying up of product pipelines. These 
problems of maturity became urgent for both agrochemical and pharmaceutical companies in the late 
1980s. They are an indication of a sector that is ripe for a period of creative destruction where new 
companies with a range of different innovation models challenge the status quo. 
 
Biotechnology was expected to provide this challenge but most industry-watchers point to its failure to 
rejuvenate product pipelines. However, there is an alternative explanation.  Biotechnology may have 
succeeded in enabling pharmaceutical companies to ride out their maturity problems for at least 
another ten years, contributing to preventing major disruption of their innovation model and a slide to 
become mere producers of commodity chemicals.  
 
Comparing cases – degrees of disruption 
This analysis compared three case studies, the impact of GM crops on the agrochemical industry and 
of pharmacogenetics and stem cells on the pharmaceutical sector, to identify why some innovations 
fail to have the predicted disruptive impacts, while others are more disruptive than expected. An 
innovation that challenges a sector’s internal R&D model and at the same time its regulatory and 
market environments is much more likely to be seriously disruptive of the sector than one which only 
affects one of these areas. 
 
GM crops proved to be highly disruptive of the innovation model of the agrochemical industry because 
of their simultaneous impacts on company R&D (requiring a shift from chemical to biology-based 
development and production systems), on markets (selling seeds is a very different business from 
selling pesticides), and on regulatory systems (the European Union deemed it necessary to develop a 
new regulatory system from scratch to deal with this new product type). There are some important 
lessons to be learned by the pharmaceutical sector from the earlier experience of the agrochemical 
industry with GM crops. 
 
With pharmacogenetics, companies have been able to exert more control over the way the innovation 
is being incorporated into the innovation system. They are attempting to guide market expectations 
and at the same time focusing on applications which will avoid potential market disruption, and they 
are also influencing the plans and expectations of regulators as they consider modifications to 
regulatory systems. Pharmacogenetics therefore seems unlikely to be disruptive for the 
pharmaceutical industry. 
 
On the other hand, stem cells, as with GM crops, could have major simultaneous impacts on 
innovation systems, markets and regulatory systems, in a manner that is much less controllable by the 
multinational companies than is pharmacogenetics.  For stem cells, an important difference from GM 
crops is that so far pharmaceutical companies are only planning to use the technology in an 
incremental manner, as a tool to develop new and better drugs, and not to develop products based on 
stem cells themselves.  
 
Regulatory – Technology Interactions 
GM crops were almost totally disruptive of agrochemical innovation systems but they would have been 
a much less disruptive innovation for seed companies of any size. However, once the agrochemical 
industry had decided to focus its future innovation system on GM crops, these other players were 
either bought out by agro-biotechnology companies or left the field, as for example did Unilever. One 
could speculate that, if GM crops had been developed by seed companies, European regulators would 
have been less likely to erect such an onerous regulatory system, although the products could still 
have been regulated effectively. 
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A similar situation arises for stem cells. They would be highly disruptive of pharmaceutical R&D 
systems, markets and possibly also regulatory systems, but largely an incremental innovation, for 
example for a small tissue engineering company. Whether the multinationals or the tissue engineering 
companies take the lead in developing stem cells as products will depend mainly on the still-evolving 
regulatory systems. If this becomes so onerous that it is impossible for small companies to continue to 
operate independently, then stem cells will be an incremental rather than a disruptive innovation for 
pharmaceutical companies. On the other hand if NBFs are able to develop the technology 
independently, then it may become externally subversive of pharmaceutical innovation systems rather 
than internally disruptive. 
 
The research community and the industry have so far paid little attention to the role of regulatory 
systems in determining the kinds of company that are able to develop innovative technology and the 
nature of, and markets for, the products themselves. 
 
The future of “big pharma” 
The agro-biotechnology sector has already seen major change and radical re-structuring of its profit 
models, at least partly as a result of its incorporation of GM crops within its product range. Companies 
in this sector are now no longer divisions of joint companies with pharmaceutical companies. They are 
less varied, less powerful and less able to withstand disruptive shocks than they were previously.  
 
It is conceivable that pharmaceutical multinationals could continue to survive in their present form 
despite the alleged unsustainability of their innovation models. However, this model is being 
undermined, not only from within through the problems of maturity, but also through regulatory and 
market challenges, with demands for cheaper drugs, regulatory changes encouraging drugs to be 
developed for small niche markets and an increasingly negative public image of the sector. These 
factors were also part of the environment that contributed to the disruption of the agro-biotechnology 
sector. 
 
The pharmaceutical innovation sector is now becoming more diversified – it is still dominated by the 
pharmaceutical MNCs but the balance of power is slowly shifting and impacts from regulatory systems 
and market structures are the primary influences likely to speed up the rate of change.  
 
If, as we propose, disruptive change in pharmaceutical innovation systems is increasingly inevitable, it 
will be important for the delivery of medical benefits to the public that this change is balanced and 
carefully managed. The key to achieving this is through evolution of the regulatory system – regulatory 
change needs to be accompanied by a good understanding of the subtlety and complexity of the 
interactions between regulation and innovation in life sciences.  
 
Innovative biotechnologies currently being developed include synthetic genomics, pathway and 
systems biology, genetic databanks, cell banks and stem cell based therapies, pharmacogenetics, nano-
biotechnology, new sensors and diagnostic technology, biopharmaceuticals. These developments are 
being facilitated through new initiatives such as translational medicine, intended to speed the passage 
of biotechnology related innovations in health care “from bench to bedside” through better integration 
of technological approaches to development and delivery of innovations in both public and 
commercial sectors.  
 
Many of these currently hot topics will have become commonplace or will have disappeared from the 
lexicon beyond 2012, to be replaced by an even bigger range of new ideas and ambitious R&D 
agendas. Many of these developments are highly interdisciplinary and we are already beginning to see 
“convergence” of innovative strategies between biotechnology, engineering, chemistry, physics, 
nanotechnology and information technology in ways that are likely to transform what we currently 
think of as the bioeconomy. This convergence of innovation strategies is being driven by the 
increasing realisation in scientific communities of the benefits of interdisciplinary research in 
removing some of the bottlenecks that can occur through single-discipline approaches and of how 
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cross-disciplinary contributions can greatly speed up the delivery of fundamental research outcomes 
and also the translation of these outcomes to practical innovations.15  
 
An alternative vision of convergence, in the societal rather than the scientific context, arises with so-
called P4 Medicine, being promoted by Professor Leroy Hood – medicine that is predictive, 
preventive, personalised, and participatory. The prediction is that P4 medicine will be “cheap and 
available to the entire world”;16 however, the basis for this expectation focuses only on the scientific 
possibilities and ignores the role of regulation in enabling or constraining particular types of 
innovation.  
 
It is difficult to envisage which new areas of technology innovation are likely to be competitive with 
biotechnology between now and 2030. There will be strong competition between different areas of 
development within biotechnology for a decisive role in the future of the bioeconomy, but there is no 
apparent competitor for biotechnology-driven innovation per se as the key determinant of the nature of 
the future health care sector. 
 
2.2 Government Policies and Regulation (the regulatory system) 
One of the key factors in determining the fate of all novel biotechnologies, and hence their 
contribution to the bioeconomy, will be the type of regulatory system chosen to determine their safety, 
quality and efficacy before they are registered for use. In health-related technology it is a common 
observation that an onerous and lengthy set of regulatory hurdles favours bigger companies (with the 
corollary that the range and inventiveness of new technology developed is more limited). In the 
context of biotechnology, this can be illustrated by the large number of small innovative companies 
working on diagnostics, devices and tissue-based therapies (so far relatively lightly regulated areas) 
with the relatively small number of long term market entrants among companies developing new 
drugs. 
 
Mainly through the requirements for clinical trials, we have seen a fairly relentless increase in the 
regulatory burden for both small molecule and biotechnology drug development. Major changes in 
regulatory systems were often made in response to evidence of gaps in current provision, for example 
the introduction of teratogenicity testing for new drugs in response to the thalidomide tragedy. The 
increasing maturity of the sector has also been responsible for some of this regulatory escalation – 
increasingly large samples of patients and longer timescales are needed in clinical trials to demonstrate 
additional benefits from molecules that do not represent a radical departure from previous classes of 
drugs, described as “me-too” drugs. 
 
There is also an increasing regulatory burden in areas such as diagnostics and tissue engineering where 
the regulatory system that has until recently been “light touch” is being brought more into line with the 
regulations for drugs under the jurisdictions of the FDA and the European Medicines Agency 
(EMEA.) This extension of regulatory oversight to new types of product will potentially squeeze out 
small companies that were previously able to survive with relatively small profit margins but will not 
be able to generate sufficient profits to support a longer and more expensive development period. 
However, these areas of innovation will not necessarily be taken up by multinational companies, 
particularly if the technologies in question would lead to smaller, more segmented markets or even to 
the disappearance of some lucrative markets for drugs for chronic diseases. Pharmacogenetics is a 
                                                 
15  To give a (superficially) simple example, a stem cell scientist needed to be able to measure the oxygen 
balance within the cells she was culturing. She approached an engineer in a neighbouring department and 
within 10 days he had developed a nano-device capable of doing what she wanted. 
16  Kautz R., (2007), Systems Biology and Systems Medicine: presentations by Lee Hood at the Barnett Institute 
of Chemical and Biological Analysis. www.barnett.neu.edu/BInews_060301/HoodSummary.htm, accessed 
on 07/10/2007 
 16 
© OECD International Futures Programme 
current example of such forces at work, where the commitment of multinational companies to this area 
of innovation is increasingly muted, compared to the enthusiasm of research scientists and 
regulators.17 
 
Although regulatory inflation has indeed been a feature of the health care area in general, there are 
some areas where regulatory requirements have been relaxed to encourage companies to satisfy public 
needs, e.g. for treatments for diseases which affect only small numbers of people and which would 
otherwise not generate a sufficiently large income to cover the costs of development. The introduction 
of FDA initiatives such as the Orphan Drugs Act, the Fast-Track System and the Critical Path 
Initiative can be seen as moves away from a “command-and-control” coercive approach towards an 
approach that facilitates problem solving between policy targets and policy makers.18 This points to 
the potential of targeted regulatory change (in the direction of being more enabling and discriminating) 
to have a significant influence on the number of products developed and the range of innovative 
approaches to treatments that find their way into development pipelines. 
 
These comments on the need for more targeted and focused approaches to the regulation of health care 
products should not be taken to imply that the risks attached to health care products are exaggerated 
and that regulatory reform should automatically mean relaxation of the regulatory burden on 
companies. However, as outlined in Box 2, changes in the nature of the regulation, from constraining 
to enabling or from indiscriminate to discriminating, or even in some cases from regulations to 
standards, can have a powerful impact on the nature of innovative products reaching the market place 
and on the speed of delivery. It should also become an increasingly important part of the regulatory 
arsenal to consider biotechnology innovation as an alternative to regulation. For example, potentially 
self-replicating nano-biotechnology systems that could become part of health care arsenals by 2020 
could be regulated by requiring any such product to be controllable through the incorporation of a 
“self-destruct” mechanism that is activated either automatically or remotely by a specific signal, rather 
than by using regulation to ban potentially useful developments. Likewise, where there is concern 
about the potential carcinogenicity of stem cell-based or genetically engineered tissue therapies, the 
introduction of a “suicide gene” into the cell structure could be considered as an option to guard 
against this outcome, rather than conducting extensive clinical trials to demonstrate total absence of 
this risk. 
 
Having operated for some time with the prevailing regulatory systems of the United States and the 
European Union, China and India are now following these systems in setting up their own regulations, 
primarily with the aim of ensuring that the products of companies based in these countries will be 
acceptable to American and European markets as well as to their increasingly significant home 
markets. The advantages of this policy currently outweigh the disadvantages. However, in future these 
increasingly powerful components of the bioeconomy may see a competitive advantage in leading 
regulatory reform so as to encourage more innovative health care sectors to develop, initially for their 
large and increasingly wealthy home markets, and perhaps also to encourage change in the United 
States and European regulatory systems. 
 
In addition to regulatory systems, government policies for the promotion of innovation are also highly 
relevant to the future shape of the bioeconomy. Public funding for basic bioscience in Europe and the 
United States has been increasing since the 1970s and this trend seems set to continue. In addition, 
countries in other parts of the world (including newly industrialising countries like China, Korea, 
Singapore and others such as India, Cuba, and Brazil) are also investing increasingly in biotechnology 
in order to promote their international competitiveness. Charitable funding of bioscience research has 
                                                 
17  See Box 1 and Note 8 
18  Milne C-P., J Tait, L. Cabanilla and J. Wegner (2007), Evolution along the Government-Governance 
Continuum: impacts of regulation on medicines innovation. (Manuscript in preparation) 
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also reached unprecedented levels, and organisations such as the Gates Foundation are bringing new 
modes of operation to the areas where they are investing (AIDS and malaria in developing countries).  
In parallel with this steadily increasing scale of investment there are signs of mounting frustration over 
the low success rate in developing useful products from the science funded by governments and 
charities. This has lead to further public funding in areas such as translational research in an attempt to 
facilitate the path of innovative new products to commercial markets or to application in health 
services and it could also lead to a new set of voices attempting to influence the course and targets of 
regulatory change. 
 
At a more general level, variation in the over-arching ethos of national governance approaches 
contributes to regulatory differences, for example between the United States and the European Union, 
which have had major implications for the development of the global bioeconomy. By 2012 we may 
have seen the emergence of an internationally recognised regulatory system for health care products 
and processes, or at least have a clear indication that it is beginning to emerge. However, it is also 
possible that current splits will have been reinforced and new splits will have emerged, making the 
realisation of a global regulatory subsystem even less likely than it is today. 
 
Bezold and Peck19 have made some detailed predictions about the future of drug regulation as 
influenced by innovation in biotechnology and information technology and conclude that there will be 
a continuing need for government regulation of pharmaceuticals, probably led by an international 
agency, but that this regulation will focus mainly on regulation of the quality of the knowledge base 
used as evidence for increasingly complex health care decisions. Their paper considers a range of 
interactions, including new approaches to clinical trials, the rise of combination therapies, empowered 
and better informed consumers with the right to decide what risks they want to take, and changes in 
health care delivery (more evidence-based and building on increasingly universal electronic health 
records). Their paper thus recognises the possibility of dramatic and unilateral regulatory reform, not 
necessarily carried out in collaboration with the pharmaceutical industry sector, but they do not 
consider the implications of such reforms for companies, health care providers, other actors and for the 
functioning of the bioeconomy as a whole. 
 
2.3 Health Care Delivery Systems 
As noted above, health care delivery is systemic at the national, but not at the global level, and it may 
be unduly optimistic to expect these national systems to converge on a global model by 2030. In the 
developed world, biotechnology-related innovation, and the increasingly costly treatments which have 
characterised this area so far, are placing strains on the delivery systems of European countries which 
have a strong element of public provision of health care and also on those of the United States with 
their focus on privately funded health insurance, but with a large proportion of the population not 
covered by such provisions. The ideal model for a health care delivery subsystem in a developed 
economy may turn out to be some combination of publicly and privately-funded provision, but there is 
no evidence so far of such a convergence. The combined impacts of privatisation of health care 
systems and personalisation of care are difficult to predict. 
 
The absorptive capacity of the health care delivery system in any country or region is very important 
for the success or otherwise of the bioeconomy, in that it has so far determined the fate and 
profitability of innovative technology developed by commercial companies, i.e. the size of the market 
for innovative products. The labour market for health workers is growing and makes up a large 
percentage of formally employed people (including the movement of labour around the world) as well 
as a growing proportion of family members who care for those with chronic illnesses and disabilities. 
The future shape of the health care sector will depend as much on how these professional, commercial 
                                                 
19  Bezold C. and J. Peck (2005), Drug Regulation 2056. Food and Drug Law Journal, 60(2), pp. 127-136. 
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and public stakeholders interact with one another and this will have an important impact on the future 
for biotechnology-related innovation.  
 
There is concern among public funders of research in biotechnology about the fact that many of the 
resulting innovations fail to deliver any public benefit because of a lack of a commercial route to 
market. In addition to its role in facilitating drug development and delivery, translational medicine is 
expected to make an important contribution to public sector research through facilitating the 
introduction of such innovations directly into public or private health care systems without the need 
for a conventionally commercial intermediary. The existence of novel market arrangements of this 
type in future could play an important role in extending the contribution of biotechnology to health 
care systems beyond the current dominance of the pharmaceutical innovation model.  
 
The faster uptake of biotechnology innovations in health care systems which could be part of the 
future bioeconomy, by either public or commercial routes to markets, will require the staff in these 
systems to be more technologically aware and knowledgeable and to be willing to change current 
systems where this creates an affordable advantage for patients. 
 
The concept of absorptive capacity is relevant to both developed and developing countries but it has 
been a particular focus for analyses of health care systems in developing countries.20 Countries like 
China and India that are attempting to scale up their biotechnology-related industry sector currently 
have to rely to a large extent on United States and European markets as outlets for their products. If 
the state of the health services in China and India and their absorptive capacity could be improved, 
these countries could have more freedom of action in the development of an innovative biotechnology 
based industry sector that is relatively independent of those of Europe and the United States. Cuba 
provides an interesting case where the existence of universal health care with good absorptive capacity 
has enabled a relatively small country to develop a successful independent biotechnology based 
industry sector.21 
 
Future expectations of more direct patient involvement in health care provision, including choice of 
drug-based treatments, mediated through the Internet or other forms of direct-to-patient 
communication and advertising could further challenge the roles of national health care delivery 
systems. There is evidence that this could be as much a factor in, for example, India as it is in Europe 
or the United States, perhaps helping to move towards greater regional equality in health care 
delivery.22  
 
A current move in the opposite direction is the emergence of regulatory bodies that make decisions on 
behalf of health care providers on the cost-benefit ratio of new biotechnology-based products and 
therapies. In the United Kingdom this function is provided by the National Institute for Health and 
Clinical Excellence (NICE). In terms of the systemic structure outlined for this report such 
organisations are “boundary crossing”, being based within health care delivery systems, but linking 
them to the science and industry innovation system, the regulatory system and also to advocacy groups 
representing the interests of patients.  
 
                                                 
20  ODI (2005), Scaling up versus Absorptive Capacity: challenges and opportunities for reaching the MGDS in 
Africa. London: Overseas Development Institute Briefing Paper, May 2005, ISSN 0140-8682; 
www.odi.org.uk  
21  H. Thorsteinsdottir (2007, in press) The Role of the Health Sysetm in Health Biotechnology in Developing 
Countries. Technology Assessment and Strategic Management, 19(5) 
22  This is supported by preliminary findings from a research project based in India, funded by the UK 
Economic and Social Research Council and the Department for International Development, based in the 
Centre for International Public Health Policy, University of Edinburgh. 
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Power structures in health care subsystems are also important factors in the uptake of innovative 
technology. Many current areas of medical professional expertise will be undermined by future 
innovative biotechnology developments and they are therefore likely to be resisted unless training and 
incentives are included in an overall translational medicine package. 
 
2.4 Public and Stakeholder Attitudes 
The agro-biotechnology sector has shown how a relatively small number of well-organised advocacy 
groups, backed up by an enthusiastic press campaign, can have a major impact on the development of 
innovative technology, in that case, genetically modified crops. These pressures had a direct impact on 
companies and also on the market for genetically modified (GM) crops, but they primarily acted via 
policy makers to ensure that the regulatory system in Europe, in contrast to that of the United States, is 
so onerous as to be inhibitory of innovation even by large multinational companies. Their actions have 
also greatly reduced public funding for research on GM technology for agriculture. 
 
So far, in the health care sector, pressures from advocacy groups against the development of high-tech 
approaches to health care such as those involving biotechnology have not been generally influential. 
Advocacy groups with this perspective that take an active interest in biotechnology in general, and 
also have explicit interests in health related biotechnology include Genewatch in the United 
Kingdom,23 the Council for Responsible Genetics in the United States24 and the Action Group on 
Erosion, Technology and Concentration (ETC) in Canada.25 Campaign issues so far adopted by these 
groups include genetic databases,26 genetic testing, synthetic genomics and nano-biotechnology,27 
discrimination through insurance policies, human cloned embryos and stem cell developments for 
disease treatments. Such groups generally have roots in the GM crops debates but are moving, so far 
on an opportunistic basis, to campaign on health-related issues. 
 
An important tipping point in the European GM crops debate came with the development of a 
powerful advocacy coalition linking environmental, consumer and third world groups in a co-
ordinated campaign against GM crops. However, so far challenges from advocacy groups with health-
related concerns have been balanced by those of patient groups demanding faster development of 
biotechnology-based cures and treatments for diseases. Nevertheless, an effective coalition promoting 
an anti-technology campaign in the health care area could be triggered by major unpredicted and/or 
unregulated problems in new biotechnology-based products, actions by companies or scientists that 
are considered by the public to be unethical or irresponsible, and/or events that undermine the trust of 
patient groups in the pharmaceutical industry. A few such events have occurred recently and if many 
others emerge over the next 5 to 10 years, they could potentially build up in the public framing of 
biotechnology-based health care until they spill over into serious, co-ordinated well-organised 
opposition to health-related biotechnology in general. 
 
Such an advocacy coalition28 could emerge in the form of a system dedicated to opposing 
biotechnology-based medicine in general with a strategically co-ordinated set of campaigns on 
individual issues that attract press attention and are likely to further their overall aim. The most 
important keys to avoiding such an outcome, from the perspective of the bioeconomy as a whole, will 
be to ensure that the patient advocacy groups continue to be regarded as independent advocates of 
                                                 
23  http://www.genewatch.org/ 
24  http://www.gene-watch.org/index.html 
25  http://www.etcgroup.org/en/ (accessed 070827) 
26  http://www.privacyinternational.org/article.shtml?cmd%5B347%5D=x-347-540765 (accessed 070827) 
27  http://www.etcgroup.org.upload.publication/602/01/synbioreportweb.pdf (accessed 070827) 
28  Sabatier P. and H. Jenkins-Smith, eds. (1993) Policy Change and Learning: An Advocacy Coalition 
Approach. Boulder, Co: Westview, pp. 290. 
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patient interests, that they are not perceived as having been “captured” by industry interests, and that 
they continue to see biotechnology-based innovation as being in the interests of their members. 
 
2.5 Global Economics 
Global changes by 2030 are likely to increasingly integrate more industrialised advanced developing 
countries into the dominant health care system as well as to produce new models to solve the public 
health problems of the very poorest. Key impacts will include: big increases in affluent groups from 
the South; increased scientific, technological and industrial capabilities and competitiveness of the 
most industrialised developing countries; and, development of new finance models to solve the worst 
problems of global diseases of poverty. 
 
An important impact of global economics on health-related biotechnology will arise through increased 
affluence and discretionary spending, enabling more people to afford expensive health care 
technologies to prolong life or to improve the quality of life. Particularly important will be the 
increasing affluence of the much more numerous middle classes in India and China, providing a 
market for innovative health technologies in these countries.  
 
General globalisation-related trends, for example in international trade, are expected to continue or to 
increase. However other, more specific aspects of globalisation will also be relevant to the health 
bioeconomy, including the continuing trend to ever-larger company size in the pharmaceutical sector, 
along with a greater focus on out-sourcing specific company functions to the most cost-effective 
locations, and inexorable pressures for ever-increasing profit margins. Companies and subsidiaries in 
India, China and the top ten developing countries will be partners of choice in certain health care 
niches, both for the production of health therapies, and in the institutions that may emerge. 
In the context of profit margins, numerous analysts have pointed to the relatively low profit margins 
associated with biotechnology’s contribution to the health economy.29,. This will continue to be a 
source of tension for the development of the bioeconomy and is already leading, for example, to 
innovative financing models for drug development in future, for example royalty streams, clinical 
research organisation (CRO) -linked financing and collaborative development financing.30 
 
Public private partnerships (PPPs), often involving major charitable organisations such as the Gates 
Foundation, are another increasingly influential approach to supporting biotechnology-related 
initiatives that are unlikely to be funded through venture capital or multinational company investment. 
At present, the main focus of attention is the development of new models for the top “neglected” 
diseases of poverty. However, if public-private models are developed successfully, they could become 
a more general feature in the translation of new products and processes into therapies and well-being. 
In the future globalised economy, large companies in India and China are likely to become 
competitive with, and comparable in size to, European and American multinationals well before 
2030.31 Increasingly they will achieve this on the basis of innovative performance as their cost-of-
labour advantage will probably not extend much beyond 2015. Per capita incomes in general are 
expected to increase in these countries by 3.1% per annum and the rate of increase is likely to be 
greater in the professional classes most involved in the bioeconomy.  
 
                                                 
29  Pisano G.P., (2006), Can Science be a Business? Lessons from Biotech. Harvard Business Review, October 
2006, www.hbr.org (accessed 7th December 2006). 
30  Kessel M. and Frank, F. (2007), A better prescription for drug development financing. Nature Biotechnology, 
25(8), pp. 859-866. 
31  Wield D., J. Chataway and D. Kale (2007), “Frameworks for Pharmaceutical Innovation in Developing 
Countries: the Indian Case”, Special Issue Technology Assessment and Strategic Management, 19 (5). 
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2.6 Demography and Human Resources 
World population is expected to continue to increase up to 2030, mainly in developing countries, with 
slow or even declining growth in the more advanced economies. The steadily increasing life 
expectancy in all countries is largely related to improved health care, although AIDS-related infections 
could reverse this trend in some countries that are not able to implement effective treatment regimes. 
Currently unknown diseases that are expected to emerge in future could have similar impacts on life 
expectancy to that of AIDS today. 
 
In all countries these larger populations are also expected to be better educated, resulting in more 
discriminating consumers of health-related technologies and also more skilled workforces. 
 
2.7 Climate Change 
An important direct impact of climate change on heath care systems is likely to be through 
encouraging the emergence of new diseases or the spread of existing diseases to new areas. New 
diseases can emerge as zoonoses where people come into contact with animal disease hosts to which 
they have not previously been exposed, or diseases can spread to new areas through movement of 
insect vectors in response to warmer or wetter climates. Where climate change leads to water 
shortages and crop failures, the movement of large numbers of people as refugees can increase the 
incidence of life-threatening diseases and spread them to new areas, in addition to the impacts of such 
changes on the economy in general. 
 
A race is being perceived by health policy makers between disease development and the development 
of biotechnology-based solutions to these problems, which is providing a major spur to in innovation 
in diagnostic technology, antibiotics and vaccines.32 
 
2.8 Security 
National security considerations are most likely to impact on the health bioeconomy through increased 
investment in infectious disease detection, prevention and treatment, stimulated by expectations of 
terrorist attacks. Such investments in the next ten years will begin to deliver successful technological 
innovations by 2015. 
 
Security issues may also lead to international imbalances in regulatory approaches, making it more 
difficult to harmonise regulations to create an equitable innovation environment. There are indications 
that researchers and policy makers in the United States are more concerned about the security 
implications of synthetic genomics than are similar groups in Europe, although this situation could 
change rapidly at any time over the next ten years. The extent of regulation in the name of security 
will be an important driver of this and other areas of biotechnology innovation, as will the nature of 
that regulation – some forms of regulation will be more inhibitory than others. To give an example 
from synthetic genomics, because of the security implications, it is unlikely that light-touch or self 
regulation, as is being advocated by many of those involved in this area, will be the chosen pattern of 
regulation. A regulatory system driven by homeland security considerations may inhibit many 
potential health care benefits (e.g. the ability to synthesise new complex drug molecules more cheaply 
or the ability to develop vaccines and antibiotics targeted to new diseases more rapidly). So far the 
European Union position on the regulation of synthetic genomics is more focused on product safety 
                                                 
32  Brownlie J., C. Peckham, J. Waage, M. Woolhouse, C. Lyall, L. Meagher, J. Tait, M. Baylis, A. Nicoll, 
(2006), Foresight. Infectious Diseases: Preparing for the Future. Future Threats. Office of Science and 
Innovation, London. 
 http://www.foresight.gov.uk/Previous_Projects/Detection_and_Identification_of_Infectious_Diseases/Report
s_and_Publications/Final_Reports/T/t1.pdf  (accessed 061106) 
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regulation rather than homeland security, but even here there is no guarantee that the regulatory 
system chosen will avoid unnecessary inhibition of innovation (See Box 2). 
 
Restrictions on the flow of information in the interests of security could be just as potentially 
inhibiting of innovation in biotechnology as are regulatory initiatives.  
 
2.9 Developments in Animal Health Drivers and their Interactions 
with Human Health Care Systems. 
Box 3 outlines some potential biotechnology-related drivers of animal health, the implications of these 
developments for animal health itself and, where relevant, the interactions with, and impacts on, 
human health care systems. Commercial activity in this area is currently approximately 3% of that 
related to human health, but some biotechnology related developments in animal health care and also 
the development of new diseases in animals and their potential transmission to humans could result in 
a much increased emphasis on animal health care per se and also its interaction with human health 
care systems. 
 
3. Health Care Scenarios: Interactions among Drivers in 
Determining the Rate and Direction of Change in the Health 
Related Bioeconomy. 
 
Closely coupled interacting systems like the health care sector with its intimate inter-twining of 
companies, markets and regulatory systems can be very robust and resistant to change. However, 
when change does come it can take place dramatically and surprisingly rapidly if it happens 
unexpectedly, particularly if changes occur simultaneously, within companies, in markets and in 
regulatory systems.33 The pressures for change are indeed building up in all three areas, but for the 
moment they are aligned in different directions, in many cases so as to inhibit technological innovation 
in some key areas and also to restrain the development of some new markets.  
 
Large pharmaceutical companies are currently the dominant players in the bioeconomy, although not 
in areas of health care delivery that do not relate to biotechnology. However, the overall sustainability 
of this dominance is increasingly being called into question.34 The scenarios developed for this report 
presume that this instability will continue to be problematic beyond 2015 and that between then and 
2030 we will see either a continuation of the current mixed and somewhat dysfunctional “muddling 
through” or a “rapid change” involving a managed transition in the health-related bioeconomy.  
 
These scenarios are a tool to achieve the project goals – to maximise the desirable features of the 
bioeconomy and to minimise negative outcomes or missed technological opportunities. Previous 
research has shown that perceptions of desirability in outcomes can vary across different 
constituencies – what is seen as desirable from the point of view of actors involved in health care 
delivery may be different from the perceptions of managers in large multinational companies and this 
will differ again from the perceptions of managers in SMEs, and so on. These variations in perceptions 
among key actors in the scenarios, and how they are translated into future behaviours will have 
important impacts on the eventual smoothness of the transitions envisaged. 
 
                                                 
33  See Note 8. 
34  See for example the latest in a long series of similar articles in Nature Journals: Anon (2007) “Time for a 
Medical: the pharmaceutical industry is struggling to adapt to a harsher political environment” Nature, 447, 
pp. 507-8. 
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Attempting to predict future technology, policy and other developments and their influence on 
complex systems is a highly uncertain exercise beyond the timescale of a few years. Many of the 
trends and bottlenecks which will determine the future of the health-related bioeconomy are evident 
today, but there will be others which we cannot predict. In addition, as noted at the beginning of 
Section 2, interactions among drivers will determine the future of the bioeconomy and it is unlikely 
that any single factor will have a dominant influence. It is also important to consider the timing of 
emergence of changes in drivers – changes that occur simultaneously can have a powerful mutually 
reinforcing effect or alternatively could cancel one another out; likewise changes that are separated by 
a period of years can build one on the other in a synergistic manner or alternatively the time lapse may 
mean that the opportunity for an impact has been missed.  
 
The following scenarios explore possible directions for change up to 2030 and the influence of these 
changes on the bioeconomy as a whole. The nature, extent and rapidity of change in the health-related 
bioeconomy will depend on all the drivers outlined above, and also on:  
 
 new technological developments, how they interact with one another and with prevailing 
health care systems; 
 the regulatory systems that evolve to ensure safety, quality and efficacy of new developments; 
and  
 the responses of markets, consumers, key actors in a range of settings, and health care related 
advocacy groups. 
 
The first scenario, Muddling Through, assumes that tensions among key actors are exacerbated by 
narrowly focused thinking and insufficient attention to the tensions and interactions in the system as a 
whole, leading to an outcome which is different from that of today but is also sub-optimal and locally 
dysfunctional. The second scenario, Rapid Change, assumes that the key actors in the system are able 
to reach a broad, common understanding of the factors driving change and of the range of options 
open to them, and collaborate in ensuring a transition to a new health-related bioeconomy which is 
radically different from that of today.  
 
To facilitate thinking about these future events, the scenarios are presented first from the perspectives 
of the three key systems outlined in the introduction: the global science and industry innovation 
system; policy and regulatory systems; and national health care delivery systems; along with key 
stakeholder and advocacy groups which may in future become systemically organised. Finally the 
scenarios consider how interactions among these groups will determine the eventual outcomes for the 
future of the bioeconomy. 
 
4. Health Care Scenario – “Muddling Through” 
4.1 Introduction 
This section describes the outcome in 2030 for a health care sector which, as seems most likely today, 
remains dominated by highly competitive actors seeking to maximise the short term advantages to 
their own organisations arising from biotechnology-based innovation. In normal circumstances these 
are admirable survival tactics for commercial companies. However, they are not conducive to radical, 
systemic change. And the failure to take up opportunities for radical change when the timing is ripe is 
likely to mean that, when the inevitable change does take place, it is more disruptive for all concerned 
than it would otherwise have been.  
 
By 2015, this scenario envisages a health care innovation sector that has managed to avoid serious or 
major disruption and is even more dominated than today by a much reduced set of very large, globally 
significant multinational companies.  
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It is also characterised by a range of features that suggest a potentially failing set of organisations: 
 
 there are continually increasing difficulties in finding innovative products to fill product 
development pipelines;  
 there is a lack of funding for new technology; 
 the sector consists increasingly of pharmaceutical commodity producers with a diminished 
R&D component in company strategies;  
 there have been numerous missed technology-based opportunities and there is dysfunctional 
competition between and within companies; 
 company relationships with regulators tend to be adversarial rather than collaborative; and  
 legal actions by health care providers and patients against companies and regulators are 
increasing in number and in cost.  
 
Many people within companies and regulatory agencies had seen the need for change, but none of 
these was in senior enough positions for long enough to make a difference - many were made 
redundant or side-lined because they had promoted initiatives that were not seen as being in the 
interests of their organisation.  
 
Despite the failure to initiate major systemic change, there had been many small and even relatively 
large initiatives that were moderately successful locally. However, these were one-off developments, 
not followed up and not globally integrated and so did not achieve their full potential benefit. Local 
fiefdoms, nationally, within and between companies and among regulators, had prevented such 
potentially useful developments from having a wider influence. 
 
To take stem cell technologies as an example, early expectations in Europe and the United States for 
stem cell based therapies and even cures for major diseases had not materialised. The slow progress 
towards the development of successful therapies, combined with low returns from the relatively small 
markets for these products, had seriously inhibited public and private investment. On the other hand, 
the use of stem cells to facilitate drug development had become the dominant innovation mode for this 
biotechnology, given that companies and venture capitalists were willing to invest in that area. 
Technological difficulties in developing therapies had contributed to this change of emphasis, but the 
major influencing factor was the increasingly lengthy and stringent regulatory system that was built up 
from 2007 in these countries for stem cell-based therapies. 
 
By 2015, Chinese and Indian pharmaceutical companies had grown along with their home markets and 
had continued to penetrate United States and European markets for commodity products. This was 
particularly the case for Chinese companies, given that China had been much more successful than 
India in developing a widely available, publicly funded health care delivery system. However, even by 
2015, the pharmaceutical industries in these countries had not been able to develop sufficiently robust 
R&D pipelines to cover the costs of failed products and to overcome the hurdles controlling entry to 
R&D based drug development in these markets.  Given that Chinese and Indian regulators had 
continued to follow the Western regulatory models of the EMEA and FDA, and that their cost of 
labour advantage had been considerably eroded by that time, pharmaceutical companies in these 
countries had little comparative advantage over companies based in Europe and the United States and 
some of the key companies were now owned by European and United States companies. 
 
Unlike pharmaceuticals, in the case of stem cell based therapies, China had developed a much more 
permissive regulatory system than those of the European Union and the United States. Since the risks 
that had been predicted for these therapies (e.g. cancer and zoonotic disease transmission [arising from 
the use of animal products in the early stages of stem cell development]) did not emerge with these 
more permissive regimes, this had been greatly to the advantage of the Chinese. China also maintained 
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a very generous level of public investment in the science, with the result that such therapies were 
widely and affordably available in China and there was a flourishing health tourism sector.  
 
These two examples, pharmaceuticals and stem cells were characteristic of the health related 
bioeconomy by 2015. The pharmaceutical sector, globally, remained resistant to fundamental change, 
with a continuation of current trends towards increased costs of drug development along with a 
declining rate of emergence of new approved products. This situation was reinforced by the 
increasingly global reach, and unreformed nature of the regulatory systems that were dominated by the 
FDA and EMEA. Likewise, for stem cells and other non-drug related developments, the European 
Union and the United States continued to place increasingly onerous regulatory hurdles in the path of 
innovative therapies, following the earlier pattern for pharmaceuticals.  However, the emerging 
economies of the world in China, India and South America had developed their own approach to 
regulation and as a result had much more flourishing sectors in these niche areas. 
 
This section explores the outcomes from 2015 to 2030 for a health care sector that has remained 
resistant to change, and dominated by the pharmaceutical sector, at least in Europe and the United 
States. 
 
4.2 Science and Industry Innovation Systems – resistance to 
change 
4.2.1 The economic context 
From 2015 the product portfolios of European and American multinational companies became 
increasingly reliant on commodity products. R&D based activity continued, and high value-added 
products were still developed for relatively smaller but high value markets. However, the high cost of 
meeting regulatory requirements meant that the price of each product was still high enough to severely 
limit the number of such markets that were viable.  
 
These circumstances applied equally to Indian and Chinese pharmaceutical companies so that they 
were also not able to progress to become R&D-based companies producing high value-added products 
as had once been their ambition. The large populations of these countries, the emergence of a large 
middle class sector and the increasing availability of public sector health care for the poor did give 
Indian and Chinese companies some competitive advantage in their development of commodity drugs, 
but were not sufficient to create more than a small number of viable markets for patented products. 
The very large size of the markets in these countries did give some competitive advantage to locally 
based companies, but they were still subject to competition from United States and European 
companies and, despite progress in both publicly and privately funded health care provision, 
limitations on willingness and ability to pay were still a major constraining factor. 
 
The availability of venture capital funding for SMEs from 2015 continued the declining trend that had 
been apparent since the beginning of the century. There was increasing competition from more 
lucrative, less long term and less uncertain investment opportunities. Also, data on the relatively poor 
historic performance of investment in life sciences was being increasingly widely emphasised35 and 
confidence in the sector was being eroded. There were thus fewer SMEs contributing to drug 
development, resulting in an increasingly impoverished innovation environment.  
 
This trend continued despite the increase in public sector investment in translational medicine that had 
been intended to bridge the venture capital (VC) funding gap. Public sector investment in translational 
medicine for products other than pharmaceuticals, had been relatively successful. However, attempts 
                                                 
35  See note 29, Pisano, 2006. 
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to use public funding to take pharmaceutical products further along the development path where they 
would then be taken up by the commercial sector had been largely unsuccessful. 
 
4.2.2 The industry structure 
The trend to outsource early stage R&D activities that had begun in the 1990s also continued unabated 
through 2015 so that the primary expectations of any new SME in this sector were unchanged – 
success for them would constitute licensing out viable products to a multinational company or being 
taken over by it. However this increasing reliance of pharmaceutical companies on external sources of 
innovative products coincided, as noted in the previous paragraph, with a reduction in the number of 
available SMEs, leaving the multinationals increasingly short of new innovative products to take to the 
market.  
 
By around 2020, this situation was leading multinationals to begin to re-invest in in-house R&D 
divisions and also to invest externally in earlier stage research within SMEs, but this is a long term 
strategy under any circumstances and it becomes increasingly difficult when funding is constrained. 
By 2030, the trend to ever-increasing costs of R&D, combined with reduced numbers of new products 
appearing on the market and lower profit margins was still continuing. During the period 2015 to 
2030, following a trend that had first become apparent in agro-biotechnology companies in the early 
2000s, several of the major pharmaceutical companies stopped conducting R&D for new drug 
development and became producers of commodity chemicals, alongside the relatively new 
commodity-based, generic pharmaceutical companies. 
 
This highly competitive, operating environment for the pharmaceutical industry also accelerated the 
trend in acquisitions and mergers.36 There were fewer large multinational companies but the potential 
increase in size of the merged companies was offset by the persistent erosion of profit margins and 
regular downsizing of the merged companies. 
 
Up till around 2010 an important component of the pharmaceutical sector had been the middle-sized 
pharmaceutical companies. Although multinational, they focused on a narrower range of products than 
the large multinationals, often concentrating exclusively on, for example, cancer therapies, vaccines or 
central nervous system treatments. Given their structure and innovation models, these companies 
would have been able to cope more effectively than large multinationals with the smaller, niche 
markets that were becoming the most common outlet for the sector. However, beyond 2010, almost all 
of these companies had been taken over by multinationals, in some cases in competitive financial deals 
which were described at the time as extravagant. 
 
4.2.3 The role of innovative technologies 
By 2015, several innovative technologies were indeed contributing on a routine basis to drug 
development, As noted in Section 1, biotechnology continued to have a similar role to that 
observed in the 1990s and 2000s, where it enabled the multinational pharmaceutical 
companies to remain profitable (and unassailable by alternative approaches) on the basis of an 
innovation model that was widely seen as fundamentally flawed.  
 
The time to market from initial discovery was reduced to an average of around ten years and 
the number of molecules rejected in later stage clinical trials declined and this offset to some 
extent the continuing challenges to the viability of the pharmaceutical sector through to 2030. 
However, it was not alone sufficient to free up the sectoral innovation system in a manner 
                                                 
36  See note 2, Mittra, 2007. 
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which was truly path-breaking, as described in the second scenario. Several technologies 
contributed to drug development in this way:  
 
 synthetic genomics contributed to the affordable manufacture of complex drug 
molecules, meaning that some drugs which would otherwise have been rejected from 
pipelines because they were too expensive or difficult to manufacture were taken 
through to market approval; 
 synthetic genomics also contributed to the more rapid development of effective 
vaccines, enabling companies to respond to public sector demands for effective 
treatments for new and emerging diseases; 
 pathway and systems biology enabled the more rapid and accurate identification of 
druggable targets;  
 stem cell technology was used to identify at an early stage molecules that were likely 
to give rise to toxicity problems or to be less effective than expected if used as 
therapies, resulting in fewer rejected products during clinical trials; 
 the use of biomarkers at the cellular level also enabled better identification of effective 
and safe products in advance of the setting up of clinical trials. 
 
Pharmacogenetics is not included in this list. By 2015 and beyond, it was still the subject of 
protracted negotiations and discussions between drug companies and regulators. The 
companies were concerned about the ability of this technology to reduce the size of their 
markets below what would be viable for a large multinational, and increasingly (for the 
reasons outlined above in this section) their views were not challenged by companies with an 
alternative perspective. 
 
4.2.4 Interactions with regulatory systems  
Up to 2015, there had been signs of a change in the mind set of regulators to recognise the co-
dependency between regulators and the drug industry and to attempt to be initiators of change, rather 
than merely regulators of drugs.37 However, the visionary regulators willing to contemplate such a 
change were relatively few in number and the resistance of the large multinationals to such changes 
was able to limit their effectiveness.  
 
Regulatory systems for new drugs thus remained reactive to technological innovation, rather than 
collaborating with the science and industry innovation system as a whole in the faster and more 
effective delivery of public benefits from new drugs. In Europe and the United States, the pace and 
scale of development of non-drug based innovations was also affected by the rigidity of the regulatory 
systems. For example tissue-based therapies and diagnostics that had previously been relatively lightly 
regulated had been subject to new regulatory approaches that were similar to those applied to drugs 
(see Box 2). The outcome of these moves was that no small company could afford to take a diagnostic 
or tissue therapy based product through all stages of the regulatory system. In most cases these 
products also did not fit with the strategies of multinational companies (see Box 1) and so were not 
developed. Thus many potentially innovative areas of scientific development which had received 
considerable support from public funding were not developed for health care markets. 
 
However, for these diagnostic products and tissue-based therapies, as noted above, India and China 
did not follow the Western regulatory path, and these countries became global leaders in the 
development of these technologies, profiting greatly from health tourism.  
                                                 
37  See note 10, Robert Powell, 2007. 
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Several large public/private partnerships (PPPs) had been developed before 2015 with the intention of 
enabling drug development for poorer countries and neglected diseases, e.g. the Gates/Buffet/Clinton 
initiatives, together with major financing tools such as the International Financing Mechanism for 
Innovation in Medicines. These initiatives did create some momentum but the investment was also 
much less productive that it might have been because of continued restrictions on developments 
arising from regulatory constraints, the lack of venture capital investment in other areas of medical 
innovation, and the relatively impoverished innovation environment surrounding the multinational 
drug companies. 
 
4.3 The Regulatory System 
The vital role played by regulators and insurers either in enabling or in blocking the development of 
highly innovative products in life sciences is clear in this scenario. Regulatory agencies played an 
increasingly important role in the evolution of the pharmaceutical industry from the 1960s, particularly 
in acting as a barrier to entry for new potential entrants to the sector, in addition to their primary aim 
of safeguarding the safety, quality and efficacy of new products.  The parallel role of regulators in 
enabling the relatively unconstrained build-up of these very large and highly profitable multinational 
companies had been, until around 2000, beneficial for society as well as for the industry. It had 
allowed the development of block-buster drug markets and generated the revenue for further 
investment in health care R&D on a scale that could never have been supported by public funds.38 
 
However, beyond 2000, it became increasingly clear that the dominant regulatory systems in the 
United States and European Union, were beginning to inhibit innovation, particularly in the new 
biotechnology-based sciences, and at the same time were failing to ensure that products which were 
approved for marketing were not subsequently subject to costly withdrawals or, worse, expensive 
litigation. This situation prevailed well beyond 2015 because of the simplistic assumption by all 
concerned that the only way to prevent post-marketing drug withdrawals and all the attendant costs to 
a company and its insurers was to increase the stringency of regulation. As suggested in the next 
scenario, a more imaginative and free-thinking approach to regulation, alongside a more positive 
approach to some kinds of innovation, could free up drug development processes while maintaining 
acceptable levels of safety. 
 
In this scenario, as noted in section 4.2.4, regulators had begun to think about regulatory reform well 
before 2015. However, expected benefits arising from pharmacogenetics or personalised healthcare 
had been slow to emerge, partly because large multinational companies had influenced regulatory 
agencies to ensure that any changes to facilitate the passage of products based on pharmacogenetics 
remained voluntary. This was part of a general pattern where regulatory reform was not given a high 
profile in regulatory agencies, the staff assigned to the task were constantly moved to other projects, 
and the whole process continued to be undermined by the opposition of influential senior managers in 
pharmaceutical companies who were aware of the potential impact of a less stringent regulatory 
system on their company’s competitive position (see second scenario). 
 
This relative rigidity in regulatory agencies was a classic case of reluctance or inability to see the 
opportunities that were being presented to those that were able and willing to embrace systemic 
change, to become part of the new, more collaborative global innovation environment, and to work 
with new partners to stimulate innovation. Embarking on such a route presented career risks to those 
in senior positions, another important factor discouraging change. 
 
                                                 
38  See note 8 
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In this scenario, the regulatory agencies were thus unwilling to take the lead in reforming health care 
innovation systems, perhaps reinforced by a desire to extend their power so that they become the 
automatic regulators of choice for any innovative product in the health care sector. By 2015 they had 
reached a position where, at least for Western nations, all new regulations for innovative products in 
life sciences were built on the now-reinforced precedent of the drugs regulatory system with its 
extended and expensive series of clinical trials. The result was that only products and processes that 
fitted with and reinforced the drugs-based profit-model of the pharmaceutical companies could be 
developed, and those SMEs that remained active in the sector, as at present, saw no alternative future 
other than delivering services, or selling intellectual property (IP), to multinationals. 
 
Box 2 - Regulatory Systems and their Impacts on Innovation39 
To say that regulation has an important impact on the kinds of product that are developed by an 
industry sector is a statement of the obvious. In the pharmaceutical industry for example, regulation is 
designed to ensure that products for the treatment of diseases are safe, effective and of high quality. 
However, regulatory systems can, by a series of incremental changes over a long period, become 
increasingly dysfunctional and out of step with innovation in the technologies they regulate. Also, as a 
regulatory system builds up in this way it becomes increasingly complex and a change or addition to 
one set of regulations can have unpredicted implications, for example for new products in 
development or for companies outside the range of the regulations themselves.  
 
Two different types of interaction between regulation and innovation, at the macro and the micro levels 
are particularly relevant to the health bioeconomy.  
 
Impact of regulation on the structure of the pharmaceutical industry 
The lengthy and demanding nature of the regulatory system as a whole, as it has been applied to the 
pharmaceutical industry, has been a major contributor to the overall shape of the sector itself, 
including the so far unchallengeable dominance of the multinational companies. The very high costs 
and long delays entailed in taking a new product through the regulatory system ensure that only large 
MNCs have the necessary resources to operate throughout the whole innovation cycle. This barrier to 
entry for small companies has shaped the structure of the industry sector, leaving the MNCs in an 
unassailable position and insulating them from challenges to their supremacy by smaller innovative 
companies with a high growth potential. Small companies either rely on MNCs to take their products 
through to market, or alternatively they need to make themselves an attractive acquisition target, 
which in both cases means that they tailor their innovation strategies to match, rather than to 
challenge, those of MNCs. 
 
Scientific discoveries in biotechnology have begun to lead to new types of products, such as stem cell-
based therapies, for which there is no clear regulatory precedent and the typical response in such 
cases is to look for a pre-existing regulatory framework into which the new type of product can be 
fitted. An alternative option in such cases would be to design a new regulatory framework tailored to 
the specific needs of the new technology. However, the most notable precedent for this approach, the 
                                                 
39  This summary paper is based on a series of research projects carried out by Joyce Tait, Joanna Chataway and 
David Wield, beginning in the 1980s. The most recent papers based on this research are:  
 Tait J. (2007), Systemic Interactions in Life Science Innovation. Technology Analysis and Strategic 
Management, 19(3), pp. 257-277, May 2007. 
 Tait J. and C. Chataway (2007), The Governance of Corporations, technological change and risk: Examining 
industrial perspectives on the development of genetically modified crops. Environment and Planning – C: 
Government and Policy, 25, pp. 21-37. 
 Chataway J., J. Tait and D. Wield (2006), The governance of agro- and pharmaceutical biotechnology 
innovation: public policy and industrial strategy. Technology Analysis and Strategic Management, 18(2), 
pp. 1-17. 
 Milne C-P., J. Tait, L. Cabanilla, J. Wegner (2007), Evolution along the Government-Governance 
Continuum: impacts of regulation on medicines innovation. (Manuscript in preparation) 
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regulatory system adopted for GM crops in Europe, is unlikely to spawn imitators in other technology 
areas. FDA and EMEA seem increasingly likely to take on the role of overarching regulatory bodies for 
health care-related governance.  
 
Because of their influence on the power balance between MNCs and other companies in the health 
care sector this gives these regulatory agencies a particularly important place in shaping the health 
care industry sector (or sectors) of the future, whether through major structural reforms of the 
regulatory system or through more targeted approaches to particular technologies.  
 
Impact of specific types of regulation on products and companies - pesticides 
In our research on agro-biotechnology, we were able to identify specific pesticide regulatory initiatives 
that had had either positive or negative impacts on innovation processes and which could form a 
useful starting point for thinking about similar issues in developments related to pharmaceuticals. We 
distinguished among regulatory instruments on the basis of whether (i) they were perceived as 
enabling or constraining by industry managers and (ii) whether they were indiscriminate or 
discriminating among products (or in some cases whether they discriminate on a basis which is 
inappropriate to the overall policy aim). Two examples can be used to illustrate these distinctions. 
Enabling and discriminating regulation. 
 
The US Food Quality Protection Act (FQPA) 1996 offered a “fast track” approach to regulation for 
pesticides that could demonstrate a better health or environmental safety profile than products 
currently on the market. This selectively enabled some companies with societally desirable products to 
gain an advantage over others and rapidly began to change the behaviour of some companies in the 
agro-biotechnology sector. Some managers described a situation where the large number of 
candidate products with these desirable properties was making it difficult to register a pesticide without 
these benefits in an economically viable time scale. Our industry interviewees thus saw this legislation 
enabling them to compete more effectively to get certain products through to the market place faster, 
by discriminating in favour of such products. Of course it was not enabling for companies that did not 
have such products in their pipelines, although it would stimulate them to move their R&D in this 
direction in the longer run. 
 
Constraining and indiscriminate regulation.  
In contrast to the FQPA the European Drinking Water Directive (80/778/EEC), at the time of our 
research, set a low limit on the permitted level of contamination of drinking water by pesticides with no 
discrimination among pesticides related to environmental damage or toxicity to people. As a result, 
agrochemical company screening systems would automatically reject a chemical with a likelihood of 
appearing in drinking water, e.g. because of its mobility in soils. In our categorisation, this legislation 
was thus indiscriminate and acted as a constraint rather than a positive incentive as in the FQPA.  
 
Zeneca Agrochemicals gave an example of how these two regulatory instruments operated in 
practice. One of their strobilurin fungicides, widely regarded as very safe products from both health 
and environmental points of view, was the first product to be registered under the FQPA fast track 
system, but this class of chemicals narrowly escaped being rejected from the pesticide pipeline at an 
early stage because of their mobility in soils and hence the risk of falling foul of the EC Drinking Water 
Directive. 
 
The general lessons that we drew form our pesticide-based research included the following: 
 
 Some regulatory initiatives can have major, rapid and positive influences on innovation 
processes and it is more to learn more about how knowledge of such influences can be used 
constructively to help design or re-design the regulatory systems of the future. 
 Regulations appropriate to one policy area often have unexpected negative impacts when 
applied in other areas, particularly when regulators are not aware of potentially useful but 
vulnerable new products and processes under development. 
 A regulatory policy which enables positive change in industry and that discriminates among 
products on the basis of societally relevant criteria, is likely to be more effective and efficient 
than one which is indiscriminate and attempts to constrain undesirable behaviour. 
 The enabling criterion will affect the speed with which a particular regulatory policy is able to 
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exert its influence, while the extent and appropriateness of its discrimination among products 
or processes will determine its effectiveness in guiding product development in particular 
directions. 
 
Impact of specific types of regulation on products and companies – health care 
In the pharmaceuticals sector, some initiatives have discriminated among particular products with the 
intention of enabling innovation in particular directions, for example the US FDA Fast Track  and the 
Orphan Drugs Act but, as in agrochemicals, such changes are rare. The general pattern in these 
sectors has been one of gradual accretion of regulatory constraints on the development of innovative 
products for health care and hence reinforcement of the current pharmaceutical innovation model.  
Two particularly challenging areas, in the policy sense, are the development of regulatory systems 
tailored to the needs of pharmacogenetics-based innovation, and the development of stem cell based 
therapeutic products (ignoring for the moment the use of stem cells to support pharmaceutical R&D) 
(see Box 1). Both these areas are currently the subject of regulatory as well as technological 
innovation, and the outcome could be an opening up of many new innovative opportunities for SMEs.  
To support innovation in these areas of the health bioeconomy an agency could usefully focus on the 
extent to which a proposed regulatory approach is able to discriminate between different types of 
product and the appropriateness of this discrimination. For example, the more a regulatory process for 
stem cell-based therapies is able to recognise the distinctions between them and pharmaceutical 
products, and to tailor the regulatory instruments to their specific needs, the more this will stimulate 
their development by new or existing tissue engineering companies.  
 
 
4.4 Health Care Delivery Systems 
There was considerable demand in health care systems and among individual patients for the promised 
benefits from the “life science revolution” and absorptive capacity had indeed been built up in most 
industrialised countries in expectation that this would begin to be significant after 2010. However, 
given the numerous failures of the research and innovation communities to deliver on extravagant 
promises, disillusionment had become widespread. Public and charitable funding of basic science and 
of early stage translational medicine began to be withdrawn from such areas in favour of approaches to 
health care that were more based on personal fitness and diet. This coincided with an increasingly 
vocal campaign from advocacy groups that now felt they could achieve public and press support for 
their long-held views that investment in the expensive, high-tech bioeconomy was an inappropriate 
use of public money. 
 
New biotechnology-based, non-pharmaceutical, developments for health care were being marketed to 
wealthy patients who could afford to pay for them, often by travelling to India or China to receive 
treatments. However, there was a vicious cycle of interactions whereby the high cost of innovative 
developments limited the market to small numbers of wealthy patients; while the small markets for 
such products did not provide sufficient profits to fund the next generation of innovative products, 
resulting in an overall slowing down of the innovation cycle.  
 
There were many local and regional initiatives, often involving collaboration with life science and ICT 
based companies, and including significant venture capital investment, that were reasonably 
successful. However there was no clear route to capitalise more generally on such initiatives, no long 
term build-up from a series of small initiatives to something bigger and most such initiatives failed to 
become part of anything resembling a “new bioeconomy trajectory”. 
 
This situation caused resentment in the majority of patients in wealthy countries for whom such 
products were not available. In poorer parts of the world, financial constraints in the science and 
innovation sector meant that research and development on the promised products for neglected 
diseases were severely cut back. It had become clear that the charities and PPPs working in this area 
did not have the skills themselves to bring new products to market, the large pharmaceutical 
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companies lost interest in such products as their profits were ever more tightly squeezed beyond 2015, 
and the smaller companies (SMEs and middle-sized pharmaceutical companies) with whom they 
might have collaborated in such a venture had largely been bought out by the large MNCs. The feeling 
became widespread among Third World health care specialists that the enormous investment from 
charitable bodies in solving the healthcare problems of the poorer groups in society had had 
disappointing results and that this was partially due to failure of co-operation from multinational drug 
companies. 
 
Direct-to-consumer (DTC) advertising and sales of drugs and other health care products had become 
much more widespread and had greatly increased sales of, and profits from, commodity drugs with 
corresponding advantages to generic producers. However, the outcomes of DTC sales had been more 
mixed for patented products, further limiting the funding available for future R&D. DTC sales had 
also increased the problem of counterfeit drugs, particularly for the more expensive patented products, 
damaging the industry’s reputation. 
 
As noted above, lack of regulatory change had meant that personalised healthcare did not deliver on its 
initial promise and this also set in place a pessimistic pattern of expectations of benefits from the 
bioeconomy in health care systems in general. 
 
The continuing high cost of patented products that is an inevitable outcome of this scenario 
strengthened the hand of healthcare based regulators (such as NICE in the United Kingdom), leading 
to continuing refusals to accept new, expensive treatments for patients in publicly funded health 
services. However, this trend was not restricted to publicly funded areas – private health care systems, 
including those in the United States, also increasingly began to ration health care options for their 
patients. As a result, relations between health care providers and companies developing innovative 
products became increasingly acrimonious. 
 
4.5 Stakeholders and Advocacy Groups 
Interactions between patient groups, pharmaceutical companies and other health technology providers 
had generally been mutually helpful and constructive up to 2015. However, the patient groups began 
to distance themselves from commercial companies as they were increasingly accused of being 
manipulated by them, and these moves were reinforced by the increasing tendency of companies, as 
they came under pressure from a wide range of sources, to assume uncritically that their interests 
coincided with those of patient groups. It is a common feature of companies under stress from an 
increasingly complex set of sources that they lose the ability to identify, to support, and to work with 
their friends, while responding in an increasingly ad hoc way to the pressures they face. They are too 
busy responding in to each challenge as it arises to be able to develop a systemic approach to the 
company’s future. 
 
In this scenario, “Third World” advocacy organisations, including many powerful NGOs and charities 
that campaigned on behalf of poor people with inadequate diets and water supplies, and little access to 
medicines, also became increasingly influential. Their campaign message was that, despite the 
promises given, biotechnology had failed to deliver any benefits for the poor people of the world. 
 
Thus the general impression among governments and members of the public that listened to these 
groups was that biotechnology based innovation had failed to deliver benefits to the poor of the world 
and had severely fallen down on its promises to deliver benefits to the wealthy. Both sets of 
stakeholders became increasingly strident in their demands; they mounted very effective media 
campaigns, were openly critical of the pharmaceutical industry and took every opportunity to expose 
what they felt was unacceptable behaviour.  
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Patient groups wanted reform of the health care delivery system as a whole – they realised it was 
seriously dysfunctional but they had no clear ideas on what needed to be done. They were not against 
biotechnology-based innovation for health care but they wanted to see it developed through a system 
was more innovative and that could deliver benefits more rapidly and more cost effectively to wider 
groups of patients than the system prevailing in this scenario.  
 
Many of the Third World NGOs had an agenda that was similar to the patient groups, but some were 
much more radical and questioned the need for, and the benefits of, continual improvements in health 
care through biotechnology-based innovation.  
 
Despite the divergence in their long term aims, these two sets of advocacy groups formed a coalition 
in 2020 to lobby for change. The groups were very clear about what they were against, mainly the 
pharmaceutical industry. They were much less clear about what they were in favour of and if they had 
explored this in detail they would probably have disagreed about their aims. The focus was entirely on 
the pharmaceutical industry as being in need of reform with no parallel recognition of the need for 
reform in regulatory agencies. The stakeholder and advocacy groups thus became very much a “loose 
cannon” in the health care sector. 
 
4.6 Interactions and their Timing 
The relative failure of biotechnology to contribute to the health related bioeconomy in this scenario 
arose from one or two unfortunate gaps or missed opportunities in timing of initiatives, and differences 
in the stand taken by key influential individuals in the regulatory and industry sectors at different 
times. Since well before 2012 small groups of people in companies and in regulatory agencies had 
been thinking about reform of their own organisations, often coming up with novel and radical ideas 
for change, none of which were implemented before the group concerned was broken up. Small think 
tanks were set up, influential articles were written in the business press, keynote speeches were given 
at major conferences but there was no overarching vision to which these individual initiatives could 
contribute. Despite the clearly recognised need for such a vision, no influential individuals or groups 
were able to get the right combination of expertise and influence around the table at the same time and 
to orchestrate the development of a vision which was attractive to enough of the major players to take 
off. 
 
The pressure for change had not gone by 2030. Indeed it had been increasingly steadily since 2015. 
However, unlike other areas of the bioeconomy, healthcare was not achieving its potential. 
It is difficult to discuss the impact of potentially beneficial interactions which fail to take place, as was 
the case in this scenario. However, the next scenario discusses this important aspect of the process of 
achieving fundamental change in more detail in a positive context. 
 
4.7 Outcome for the Bioeconomy 
As noted in Section 1, the impact of biotechnologies on health care has so far been almost entirely 
delivered through pharmaceutical developments and what is possible in terms of biotechnology-based 
patient treatment had, up till 2015, been almost entirely determined by the multinational 
pharmaceutical companies, hence the major focus on the pharmaceutical sector and its regulatory 
system in this scenario.  
 
Even up to 2030, the health care sector was still dominated by a set of complex, rigid, long-established 
systems that were resistant to fundamental change, but willing to undertake piecemeal, non-strategic, 
incremental change when it fitted with their overall vision of the status quo as being the preferred 
future for their organisations. 
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However, as noted in Section 4.1, a crack in this dominance began to emerge in the period 2015 to 
2030, when India and China did not follow Western regulatory precedents for diagnostics and tissue-
based therapies. This was possible partly because of more permissive public attitudes to risk in these 
countries and, given that most of the risks that Western regulatory systems had been designed to 
prevent did not emerge, it was a successful strategy. It gave these countries a strong lead in the 
development of these technologies, and the extent to which Western patients were prepared to travel to 
receive treatments was an indication that the risk aversion of European and American patients was 
perhaps more apparent than real. 
 
The overall outcome in this scenario is not disastrous – it is merely seriously sub-optimal. It is 
characterised overall by conservatism, by increasingly aggressive competition between multinational 
companies and assertion of influence by big pharma (an outcome of resistance to change in that 
sector), continuing resistance to change in regulatory systems, mounting frustration in health care 
systems and increasingly concerted action against technology based innovation in general, and the 
pharmaceutical industry in particular, among advocacy and patient groups.  
 
An important factor in the maintenance of the status quo was the continued hegemony of the 
multinational pharmaceutical companies. Despite the financial pressures which they faced they were 
able to maintain a united front, particularly in their dealings with the regulatory system and with 
governments, This contrasts with the situation faced by agro-biotechnology companies where an 
important factor inhibiting their ability to deal with the challenges they faced from GM crops in the 
1990s was the break-up of the previous hegemony and the emergence of serious, public disagreements 
between companies.  
By 2030, the sector was pervaded by a general atmosphere of low-level aggression and bad temper, 
and a pervasive concern that this could erupt rapidly into very damaging levels of conflict, with no 
clear strategy for preventing it. 
 
The health care sector had long been expected to be the lead contributor to the bioeconomy up to 
2030. However, in this scenario, its contributions are much less than predicted. The pharmaceutical 
sector was no longer seen a dominant driver of the economy as a whole in Europe and the United 
States, and was ceasing to be given special attention by governments.  
 
The difficulty in finding profitable enough markets for high-value R&D-based products was leading to 
continued shrinkage in the overall size of companies and hence of the sector as a whole. 
 
Governments were continuing to fund research and early stage development of products and processes 
that were likely to lead to public benefits. However, they now recognised that such products were 
unlikely to be delivered through the pharmaceutical sector (see section 4.2.1). They increasingly 
focused on translation, either taking place entirely within the public sector or alternatively involving 
collaboration with SMEs. In this context there was a thriving SME sector, but because of the micro-
scale nature of many such markets, the companies involved were likely to remain small players and 
not to contribute greatly to the bioeconomy. 
 
Much of the hype about increased longevity arising from biotechnology-based innovation had 
disappeared and the rate of increase in lifespan had moderated. Many people, supported by modest 
improvements in health care and lifestyles, were living longer healthier lives, and were continuing to 
remain for longer in active employment, mitigating the expected crisis in pension provision. However, 
a considerable proportion of society continued to have an unhealthy life-style, counteracting the more 
positive trend. 
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5. Health Care Scenario – “Rapid Change” 
5.1 Introduction 
This scenario discusses the key factors and interactions that will shape the evolution of health care 
systems beyond 2015, assuming that the interactions are well managed so as to resolve the tensions 
that are inherent in the current health care system and to ensure an effective, if sometimes difficult, 
transition to a global bioeconomy that supports biotechnology innovation in the delivery of both public 
and private benefits, and to enable a better global distribution of health care benefits than that of the 
early 21st century. 
 
The future health scenario we envisage here had the following characteristics, as outlined in more 
detail in the following sections: 
 
 the contributions of biotechnology extended well beyond the predominantly drug-related 
developments of today; 
 it required 5 years or less, rather than the previous 10 to 15 years, to take a new product or 
process through all the stages needed for approval for use on patients; 
 the size distribution and specialisms of companies involved in health care were greatly 
extended, for example with many more middle-sized companies serving more niche markets, 
and a more robust SME sector with company strategies that were more long-term and more 
independent of the needs of  MNCs; 
 developments that emerged from public sector research institutions could more easily be 
taken further down the route to application within the public sector and could in many cases 
be taken all the way through to application within health care delivery systems, in addition to 
the previously well-worn innovation path via licensing or selling the technology to a MNC. 
 
Health care had become predominantly a service industry,40 its main business being to link the 
delivery of new and existing products and services to patients by coordinating the activities of a range 
of public and private sector providers delivering drugs, information and other health care-related 
products, services and treatments. This service industry was now led, or perhaps coordinated is a better 
term, by a new type of company that was able to harness a wider range of global networks, bringing 
together new technology, new types of expertise, surmounting regulatory barriers to innovation, and 
embracing new competition models.41 As nanotechnology, information technology and biotechnology 
become increasingly convergent at the scientific discovery level and as technologies, so did their 
business models also begin to converge, enabling new insights to be combined to deliver better health 
care faster. It was not a foregone conclusion that the leaders in this new health bioeconomy would 
emerge from the current set of multinational pharmaceutical companies. However, as we discuss, it 
was also possible that they could transform themselves and take on this role. 
 
The following sections outline the factors that led to the managed evolution of such a scenario, arising 
from the baseline state of the health care sector outlined in Section 1, in response to the change drivers 
outlined in Section 2. 
 
                                                 
40  Anon. (2006) 100-in-1: a Vision of Our Industry in 2015. DVD, Version 2.0, Information Transforms 
41  World Economic Forum (2007) Inaugural Meeting of the New Champions: Briefing Material. Dalian, 
Peoples Republic of China, 6-8 September 2007 
 http://www.knowledgeconcierge.com/WEFPublic/PDFs/Dalian2007/Briefings_EN.pdf (accessed on 070906) 
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5.2 Science and Industry Innovation System: New Strategies and 
Business Models 
5.2.1 Changes in industry structures and new innovation models 
Since well before 2015, a complex set of changes had been emerging in scientific research and 
industry innovation systems, beginning around 2007, stimulated by the perception of a changing 
balance of power, with innovative thinking about new business models being led by the World 
Economic Forum (WEF). A WEF meeting in September 2007 focused on “The New Champions” and 
“The Shifting Power Equation”, referring to a new class of leaders and innovators, the growing 
prominence of emerging economies and the increasing power of individuals, small groups and 
consumers over large institutions and producers. Advice on “making business strategies more global” 
was hardly needed by companies in the life science sector, but they nevertheless found it more 
difficult than some other sectors to respond to these opportunities, particular blockages being the 
overcoming of regulatory inertia, cumbersome R&D portfolios, and resolving the tensions between 
public and private health care providers, direct to consumer marketing, and developed and developing 
world health care systems. However, from 2015 to 2030 this new form of thinking began to deliver 
real benefits to the bioeconomy. 
 
One factor which facilitated this change to a new form of organisation in the health care sector was the 
decision in 2010 by senior management in three of the large multinational pharmaceutical companies, 
partly stimulated by the WEF “New Champions” initiative, to begin discussions about the 
development of a radically new structure for the health care sector. Meetings included representatives 
from all regions actively involved in pharmaceutical and biotechnology innovation, companies of all 
sizes and specialisms active in the health care sector, public and private health services, medical and 
health care charities, regulators, the insurance industry, and patient representatives. Managers from the 
ICT sector were also included in these meetings, initially to enable participants to learn from their 
experience of operating in a more open, collaborative, networked environment with more direct and 
active collaboration with consumers.  
 
As these discussions began to bear real fruit in the form of new business strategies, including the 
envisioning of an alternative range of potentially attractive profit models, additional multinational 
companies joined the discussions, and participation was elevated to CEO level for both pharmaceutical 
and ICT companies in some meetings. In 2015 one of the largest pharmaceutical companies decided to 
form a joint company (PATC) with a major ICT firm in order to gain “first mover” advantage in what 
they by then perceived was “the way forward” for the health bioeconomy. It took several years from 
the formation of PATC to develop the beginnings of an effective model for the new co-ordinated mode 
of operation which became known as Networked Health Care (NHC). 
 
The backing of the two parent companies, with their considerable financial clout was reinforced by the 
support and active participation of two other major financial players, the private health care insurance 
industry, particularly in the United States, and the re-insurance industry. Other key supporters that 
were actively involved in the shaping of the NHC approach included the regulators (FDA and EMEA), 
the major charities funding health care research and development, and a Patient Group Consortium 
that had been formed in 2012 to promote innovative change in the health care sector and had mounted 
a campaign in 2015 to encourage the more rapid development and uptake of biotechnology-based 
innovation.  
 
Several elements were crucial to this successful, if sometimes difficult, transformation, fundamentally 
affecting the health care sector as a whole, in a relatively short space of time. These are summarised 
below and in some cases are expanded in the following sections of this scenario. 
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1. Particularly important were the changes that had been taking place in regulatory systems since 
around 2005, starting with relatively small scale initiatives but progressing to become the 
dominant regulatory mode of operation by 2015. These changes were designed to support 
innovation in the development of drugs and other biotechnology-based innovations and to 
encourage the participation of a wider range of companies throughout the entire development 
pipeline (see Section 5.3). 
 
2. Of equal importance was the coming together of two visionary CEOs in the pharmaceutical 
and ICT companies. This is not such an unlikely occurrence as might be imagined. The 
pharmaceutical CEO was one of several in the industry who could foresee the gradual drift to 
commodity company status described in the first scenario, who wanted the company to 
become part of an alternative process with a more technology focused future and who was 
able to persuade the company’s main board to support that vision. The CEO of the ICT 
company was one of those restless individuals who liked a challenge and who was looking for 
a new outlet for their talents. PACT was built from a combination of the pharmaceutical 
company along with a very major investment from the ICT company, with the director of the 
ICT company as CEO of the combined company and a main board that included directors 
from both companies. The expertise of staff from the ICT partner was crucial in developing 
the hardware and software for the basic information network that was essential to the new 
style of operation. This new model also proved highly attractive to venture capital companies 
who, as outlined in the first scenario, had become increasingly disillusioned with the prospects 
of major profits being generated from health-related biotechnology. 
 
3. The third important element necessary to the success of this scenario was biotechnology itself. 
As indicated in Section 4.3.2, a range of biotechnologies is poised to speed up significantly the 
rate of development of drugs and other innovative technologies through to application to 
patients, and also to reduce the cost of the process. In this scenario, pharmacogenetics is 
included in this list and has a crucial role to play in the new networked health care system. Its 
propensity to increase the cost of individual products is offset to some extent by its ability 
greatly to reduce the number of rejected drugs in Stage 3 clinical trials. This results in a 
considerable increase in the number of new drugs on the market, each with a smaller market 
and hence a lower profit margin. However, since PACT’s profit model relies only partly on 
the sale of drugs this is not such a significant obstacle as it would have been for a purely 
pharmaceutical company. 
 
4. Another factor which led to the “softening up” of the environment for this kind of innovative 
step change was the new mind-set that had become increasingly prevalent in health care 
delivery systems (see Section 4.4). In the period up to 2015, public and private health care 
providers in developed and developing countries had increasingly begun to realise that 
technological innovation, including biotechnology, could provide better health care more 
cheaply than before if well managed. Major education initiatives had been set up in all 
countries with advanced health care systems to ensure that the health care sector was well 
prepared to deliver these benefits and to collaborate in ensuring that resulting innovations 
were fit for purpose. In developing countries, charitable organisations and PPPs were active in 
equivalent educational initiatives. Patient support groups had also had an important role in 
encouraging these educational developments. 
 
By 2020, PATC had two competitors, each with slightly different modes of operation, but built on 
similar principles. One was led by a consortium of Indian pharmaceutical and ICT companies and the 
other was more similar to PATC. By 2025 these three companies dominated health care provision in 
the bioeconomy and the remaining companies in the pharmaceutical sector increasingly operated 
through these companies to reach their markets more efficiently. The new approach to drug 
development, based on pharmacogenetics and a range of biotechnology-based innovations to facilitate 
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drug development, along with the new regulatory regimes meant that, from 2015, companies that were 
involved in drug development were increasingly obliged to operate through the NHC model. Those 
that resisted change either became targets for take-over by the more successful NHC based group of 
companies, or concentrated increasingly on commodity drug markets.  
 
An important aspect of the NHC approach was the involvement of a much wider range of types of 
company and product within the same organisation. Up till 2015, the pharmaceutical sector had 
outsourced to SMEs many of its early and mid-stage R&D activities or had bought in from SMEs 
products in early to mid-stages of development. The NHC approach took the flexible kind of 
organisation that the pharmaceutical sector had developed for early stage drug development and 
extended it (i) to the whole development pipeline, through to delivery to patients, and (ii) to a much 
wider range of products such as the tissue-based therapies, diagnostics and devices that we can 
envisage today along with totally novel approaches to health care emerging between today and 2030. 
The difference from the situation up to 2015, and the key to the NHC profit model, was that the most 
powerful industry sector was no longer acting as a technology gate-keeper, inhibiting the development 
of innovations that did not contribute to a drug-based approach to health care. While the profit base of 
any individual item in the portfolio of a NHC-based company was not comparable to that of a block-
buster drug, the co-ordination of a range of drugs and therapies, each with a more modest profit based, 
proved to be a much more viable and resilient approach overall. 
 
In the development of new drugs there was still a wide variety of types of relationship between the 
NHC-based companies, the now-smaller pharmaceutical multinationals and among the smaller 
companies themselves. Mergers between SMEs and middle sized pharmaceutical companies, and also 
between two or more SMEs became increasingly common. Mergers and acquisitions were still 
common but the motivation was more usually common benefits from the linking of complementary 
technologies, rather than straightforward purchase of inputs to a flagging pipeline as was more usually 
the case up to 2015. 
 
The fact that the main route to market for health care products was increasingly mediated and brokered 
via the NHC-based companies meant that contributing companies, small and medium sized, could 
succeed financially with a much wider range of innovation strategies than was the case in 2015. Drug 
development no longer dominated the bioeconomy, and the fruits of public and private investment in 
life sciences began to emerge in new and often-unexpected ways, stimulated by new types of 
partnership bringing together companies and individuals with biochemical, chemical, IT, physics and 
engineering expertise. 
 
The NHC innovation approach proved very attractive to Indian and Chinese companies working in 
both pharmaceuticals and ICT. Pharmaceutical companies in particular were able to adapt more easily 
and rapidly to this way of working than companies based in Europe and the United States. This 
became the factor most responsible for the increasing global importance of Indian and Chinese 
companies, taking a lead role in several of the new NHC based companies and being much in demand 
as partners in others. 
 
The NHC based companies were also much more able to work constructively with the large charitable 
foundations and PPPs, with particular successes beginning to emerge by 2020 in developing countries. 
Thus, by 2030, in line with experience in other industry sectors, the long term winners were clearly the 
companies that, faced with a need for creative change, had been able to re-structure their innovation 
models, even if it meant making many current products and processes redundant. Companies that 
aggressively defended the status quo in a rapidly changing environment did gain in the short term but 
did not retain their dominance in the long run. 
 
The new NHC-based companies were increasingly acting as brokers and systemic co-ordinators for 
health care systems as a whole. ICT was now in the driving seat, with leaner and more disaggregated 
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production systems and more sophisticated supply chain management. The pharmaceutical companies 
that joined with ICT based companies to develop the NHC model of health care provision were 
focused on a much broader range of products sourced from a wide range of companies. They were no 
longer directly linked to the pharmaceutical companies in existence in 2030; these had become 
middle-sized multinational companies, serving middle-sized or commodity markets, generally via the 
NHC-based companies. Most often the drugs they developed were part of an integrated package of 
products for more sophisticated health care needs. 
 
Companies operating outside the NHC-based system thus competed or collaborated with a much wider 
range of companies and health care deliverers than was the case in 2015. They were competing on a 
more equal basis and there was a greater variety of roles and responsibilities for smaller companies. 
Pure pharmaceutical companies, other than those that had collaborated in the NHC system, no longer 
had the profit margins they enjoyed in the 1990s and the early 21st century but the resulting closer and 
more equal collaboration among companies had allowed many more small companies to grow and 
develop independent innovation strategies. Following the patterns observed in other industry sectors, 
this greater variety of opportunity had led to an increase in the overall innovativeness of the health 
related bioeconomy, encouraging further investment in biotechnology. 
 
5.2.2 Changes in innovative technology 
Despite the initially sceptical assessment of the prospects for drug development arising from 
pharmacogenetics,42 by 2015 this had become the basis for the dominant model of innovation in the 
drugs industry, linked to a genetically based, targeted approach to life style changes to accompany 
drug-related therapies. The smaller more specialised markets that result from pharmacogenetics-
related innovation were now the mainstay of the new healthcare delivery system and biotechnology 
was continuing to open up new frontiers. 
 
One innovation-related factor that made it possible to develop such niche markets on a profitable basis 
was the development of new approaches to the synthesis of complex biological and chemical 
molecules. Many potential products had been rejected from drug development pipelines in the past 
because they could not be synthesised at an affordable cost, even if they could be proven to be safe 
and effective. Synthetic genomics had an important impact in this area, as did the use of GM plants, 
animals and microorganisms. 
 
Gene sequencing plus synthetic genomics is an example of a convergent technology, combining 
chemistry, physics, engineering, biotechnology and information technology to develop health care 
diagnostic and delivery systems operating at the nano scale. Such developments were facilitated by the 
existence of the new NHC based companies that could organise the collaborations across different 
disciplines required to bring such products to market.  
 
Research on stem cells had by 2020 resulted in successful and affordable therapies, based on both 
adult and human embryonic stem cells. They had reduced drug bills and done away with some 
important drug markets. However, they had also created a new range of niche markets for products 
needed to support tissue engineering therapies, either in the culture of tissues for therapeutic purposes, 
the running of stem cell banks, or to deliver cell-based therapies directly to patients. The companies 
operating in this market were the descendents of earlier SMEs delivering products related to bone 
marrow transplants or skin grafts and many had grown to be significant operators on a global scale, 
although there was also a thriving body of new SMEs emerging to exploit the introduction of new, 
innovative therapies arising from stem cells. The successful development of stem cell therapies had 
been crucially dependent on the willingness of regulators to tailor the regulatory systems for these 
                                                 
42  Nightingale P. and P. Martin (2004), The Myth of the Biotech Revolution. Trends in Biotechnology, 22(11), 
pp. 564-569. 
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novel therapies to the needs of SMEs operating in this area, rather than to model the regulatory 
systems on those already in existence for drugs in the early 2000s. 
 
The translational medicine approach to facilitating the development of innovative technologies for 
health care, begun around 2005, proved moderately successful between then and 2015. However, it 
really began to achieve its full potential with the arrival of the NHC –based approach to delivery of 
products and services for health care. Indeed, previous experience with translational medicine up to 
2015 proved invaluable in the subsequent development of the NHC model. 
 
5.2.3 New kinds of markets 
The development of innovative products specifically tailored to the needs of individual patients or 
groups of patients had meant that, although some drugs were still sold for very large markets, by 2015 
these were mainly off-patent commodities that no longer attracted high profit margins. Commodity 
markets had increased dramatically in size with the increase in affluence in newly developed markets 
such as China, India and Brazil and many of the new companies serving these markets were based in 
these countries. Charitable schemes to extend affordable health care to those parts of the world that 
were still relatively poor were further increasing the profits of the commodity pharmaceutical 
companies. 
 
Under the HNC approach, biotechnology innovation had led to the development of many more 
markets than before for new, patented, generally biotechnology-based, drugs able to generate 
attractive profit margins. However, the scale of these markets was smaller than for the block-buster 
drugs that were previously the mainstay of the pharmaceutical industry. By 2020, with the dominance 
of the NHC innovation model, these drugs were produced by middle-sized or small companies with 
specialised portfolios, companies that could work more closely and effectively with their markets and 
with other health care providers. 
 
A new market was created in 2015 by large MNCs, that contributed to the growth of the bioeconomy. 
To help boost flagging profit margins, many companies moved to sell property rights and information 
related to drugs which they had previously rejected from development pipelines, perhaps because they 
did not fit with their market strategies at the time. This formed a small but significant contribution to 
revenues of these companies and it also had a very beneficial effect on the bioeconomy by stimulating 
the development of more affordable new products by SMEs or middle sized pharmaceutical 
companies. 
 
5.3 The Regulatory System 
5.3.1 Stimuli for change in regulatory systems 
The above strategic changes in the science and industry innovation system could not have taken place 
without equally fundamental changes in the nature of regulatory systems for the health care related 
industries. The regulators involved in the discussions that began in 2015 (see Section 5.2.1), came 
mainly from the FDA and EMEA. From around 2005, regulators had begun to think constructively 
about their vital role in determining the future of the health care industry sector based on the 
regulatory routes to market that they devised and the nature of the regulatory systems involved (See 
Box 2). They had begun to make modest changes, initially of a voluntary nature, to stimulate 
innovation and encourage companies to develop personalised health care products arising from 
pharmacogenetics. An example of this kind of initiative was the FDA Critical Path Initiative. These 
modest beginnings had initially been resisted by some of the major pharmaceutical MNCs, but they 
had been embraced by others who had begun to think constructively (and at that stage only internally) 
about a future that was not dominated by blockbuster drug markets.  
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Earlier successful precedents for this kind of approach had been the Orphan Drugs Act and the Fast 
Track, designed to make new drugs available more rapidly for rare and/or life threatening diseases for 
which there were no effective treatments available.43 
 
Regulators had generally seen their role as being limited to that of framing regulations to deal with 
potential safety and efficacy issues, and ensuring compliance with these regulations. Around 2007, 
instead of seeing themselves as passive responders to events, regulators began to see their role in a 
much more proactive way. In line with “new governance” agendas44 and linked to globalisation 
initiatives, discussions began to take place within regulatory bodies about their role in stimulating 
changes in the processes and outcomes of health care innovation. 
 
The process of priming regulatory systems to see the need for change had thus begun before 2015, but 
until then these changes were piecemeal and incremental rather than systemic. The stimulus for the 
systemic revision of regulatory systems, required to enable the changes outlined in Section 5.2, was 
the series of discussions involving the ICT industry sector that started in 2015. The experience of the 
ICT sector in standard setting as a mode of governance of their industry that is enabling rather than 
constraining of innovation, was seen as one that might be applicable with some modifications to the 
health care sector. 
 
A series of creative think-tanks was set up, initially involving a restricted set of participants from the 
full range of life science companies, ICT companies, regulators, and insurance industry 
representatives. As discussions progressed and concrete proposals began to be formalised, discussion 
fora were widened to include patient groups and other stakeholders. 
 
The challenge addressed was to ensure the continued safety, quality and efficacy of new drugs but to 
do this within a system that was responsive to the new challenges being presented by life science 
innovation. There was a profound shift in the perceived nature of the problem of the failure rate of 
new drugs in Phase 2 and particularly Phase 3 clinical trials. This had been seen as a failure of industry 
innovation models but began to be seen more as a mismatch between:  
 
 the nature of new biotechnology innovations;  
 the nature of the companies that could best exploit these innovations;   
 public and patient expectations of new drugs and treatments; and  
 regulatory systems that were designed around 20th century models of drug development. 
 
The new regulatory approach that began to emerge required creative and constructive thinking from 
senior managers, regulators and analysts in life science and ICT industries, along with an enthusiasm 
for collaboration across non-traditional boundaries. Initially this group was self-selected and not 
representative of mainstream thinking in companies or regulatory systems. However as the strains in 
the 20th century pharmaceutical innovation model persisted and became more severe, new approaches 
to regulation (as with new innovation systems) began to seem, not just more attractive, but inevitable. 
The key to actual change was showing how it could be done, not merely recognising that it was 
needed. And the key to achieving change came from interaction with the ICT sector that freed up 
thinking about health care policy and regulation in a way that was seen as non-threatening by those 
involved from the pharmaceutical industry, even although it did involve very radical change. 
 
An additional feature that facilitated change was the involvement of Indian and Chinese companies 
and regulators. Their innovation and regulatory systems did not have the well-entrenches position of 
                                                 
43  See Milne et al., note 17. 
44  Lyall C. and J. Tait, (2005), New Modes of Governance: Developing an Integrated Policy Approach to 
Science, Technology, Risk and the Environment. Aldershot: Ashgate Publishing. 
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those in the United States and the European Union, and their regulatory systems were still evolving, 
initially to conform with the 20th century models then in existence but increasingly to support a shift to 
a new regulatory model more in tune with the needs of the 21st century. This move was facilitated in 
both China and India by their pre-existing expertise in ICT industry sectors and enabled companies in 
these countries to move to a more equal competitive position with companies in the United States and 
the European Union, and even in some cases to overtake them in global competitiveness.  
 
5.3.2 New approaches to phase 3 clinical trials and beyond 
As part of the new regulatory system, there was a revision of the approach to Phase 3 clinical trials, 
referred to by some as the “living license”. Rather than double blind controlled clinical trials, this 
involved patients who volunteered to take part in the trial with the risks and benefits of the treatment 
and effects on a range of vital systems being monitored centrally throughout the trial by the regulators 
as well as by local medical practitioners, using a range of IT-related innovations. In this situation, 
individuals thus formed their own controls, with real time monitoring of the effects of drugs on a range 
of biomarkers. One major benefit of this approach was the reduction in numbers of patients required 
for expensive Phase 3 clinical trials. Another benefit was the earlier rejection of defective drugs from 
clinical trials, again saving money. However, combined with pharmacogenetics, this approach also led 
to a significant increase in the number of new innovative drugs on the market, also stimulating a new 
round of basic research into new druggable targets. 
 
Another major benefit came with new non-drug based therapies arising from biotechnology-based 
innovation, such as stem cell therapies and nano-biotechnology based systemic treatments. In the early 
stages of development of these technologies, approaches to regulation were being built around 
modifications of drug-related regulation and this was proving to be extremely inhibiting of innovation. 
The new “living license” approach had a dramatic impact on the rate of expansion of innovation in 
such areas, with many more products emerging from a range of small companies operating novel 
convergent innovation models that brought together information technology and biotechnology, often 
operating at the nano scale (see Box 2). 
 
5.3.3 The shape of the new policy and regulatory systems 
Regulators’ increasing understanding of the complex interactions that bound them to the 
pharmaceutical industry sector, along with new alliances with the ICT sector, enabled them to set 
about trying to find innovative ways to deliver safe medicines to the public faster at less cost, using 
new biotechnologies and information technology to achieve this. These new policy and regulatory 
approaches opened up new opportunities for innovative SMEs to build up sustainable profit models. 
The role of the large pharmaceutical MNCs began to change from that of innovation controller to 
innovation facilitator. This approach was highly successful and by 2030, the average time to take a 
new drug or treatment through the regulatory system was five years. 
 
The new regulatory systems were more effectively coordinated internationally than their predecessors, 
but there were still significant differences between the United States, the European Union and other 
major players such as India and China. These differences reflected the different political systems in 
these regions, differences in health care delivery systems, and differences in public and patient needs 
and expectations. 
 
The new regulatory systems were fully in place by 2020, but their benefits in speeding up the scale 
and rate of biotechnology innovation had been apparent since 2015, as a series of co-ordinated 
changes began to be implemented. This had an important impact on public policy makers involved in 
science and innovation funding who had begun to question the wisdom of investing so much public 
money in life sciences, given the poor record in the translation of fundamental science into effective 
health care innovations. Funding strategies were reviewed and money continued to flow into basic life 
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science but the previous trend to direct such funding to interdisciplinary areas was now reinforced. 
There was also a dramatic impact on the flow of venture capital into the health care sector, given that 
there were more rapid and direct routes to market for innovative products and profits began to accrue 
more directly to the SMEs that were funded by venture capital. 
 
5.4 Health Care Delivery Systems 
5.4.1 New health care delivery systems 
The “Rapid Change” scenario requires as much fundamental change in health care delivery systems as 
in regulatory systems. In order to become intelligent customers for innovative technology the health 
care sector had to embrace change; to cope with shifting hierarchies as new specialisms become key to 
health care delivery; and to develop a flexible, more technologically literate workforce. In parallel 
with these pressures, patients had continued to become better informed about diseases which may 
affect them and to be more demanding about the treatment they received.  
 
This had been a bigger challenge in some countries than in others. For example technological 
approaches to health care were previously better developed in the United States than in some 
European countries, but this did not necessarily correlate with the public or private nature of health 
care provision – other aspects of national politics seemed to be just as influential in facilitating uptake 
of innovations. Electronic health care records were planned to form the basis for the NHC approach 
and the early investments in this area, particularly in the United States private health care system and 
some European Union countries, proved invaluable in the initial stages of the development of the NHC 
approach. This also gave those countries with advanced systems an earlier and easier route to benefit 
from the new approach. 
 
The Rapid Change scenario, up to 2030, envisages that there had been a convergence in developed 
countries in the scale and nature of public and private health care provision with most countries 
operating a mixed health care economy. There was much less disparity than before 2015 in the quality 
of public and private provision of health care. There still was not equality, but the differences were no 
longer so great as to lead to resentment among less privileged patients. 
 
5.4.2 New health care markets 
Markets for innovative products in the new health care sector were generally smaller and smarter, 
alongside ever-larger markets for commodity products which were now much more widely available 
than before, globally. The drugs and other products developed under the new NHC system could not 
be claimed to be cheap but they were more affordable than previous generations of products and were 
developed more rapidly thanks to the revised regulatory arrangements. In addition, because of the 
links with the ICT sector, health care products that were combined in innovative ways with standard 
home computing equipment began to be available, developing mass market IT-based innovations 
which were able to reduce further the cost of health care products. Health care based regulatory bodies 
like NICE began to collaborate more enthusiastically with companies and regulators in realising what 
they saw as an attractive and more affordable future for health care. 
 
As health care systems had become more technologically sophisticated themselves, there had been an 
increasing tendency for biotechnology related innovations to emerge directly from the medical 
profession and other health care workers. Thus the health care systems themselves became important 
innovators, creating new markets which spread directly from one health care provider to another, 
requiring new approaches to intellectual property protection and revenue generation. Alternatively a 
health care provider with an innovative idea was able to link up with a SME to develop it further and 
disseminate it more widely. The beginnings of this kind of thinking were apparent before 2015 (for 
example the slogan for translational medicine – “From bench to bedside and back again”) but it did 
not became a reality in the commercial sector till after 2015 through the NHC approach, when the staff 
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of health care delivery systems had become as familiar with the demands of innovative technology as 
they were with the more routine delivery of health care. 
 
This change was greatly facilitated by the emergence of the new type of company represented by 
PATC which could cope with much more flexible and collaborative arrangements between companies 
and public sector actors. It also would not have been possible without the changes in regulatory 
systems described in Section 5.3. Indeed the “living license” approach, which engaged more 
constructively than before with medical professionals in the conduct of clinical trials, also began to 
stimulate innovative approaches to drug development and delivery arising from the health care system 
itself. This included combined convergent technology-based therapies which were much less likely to 
emerge from any other source that did not have the direct experience of interacting with patients. 
 
5.4.3 Emergence of new diseases 
One factor that greatly facilitated funding and support for new diagnostic treatments and development 
of antibiotics was the emergence of new epidemic and potentially pandemic diseases. Relevant factors 
here included:  
 
 farm animals, or perhaps even family pets living in close proximity with humans, that could 
transmit new and potentially very serious diseases to the human population (see Box 3);  
 climate change that enabled insect vectors to colonise new areas or (through drought or food 
shortages) stimulated mass migrations that concentrated large numbers of people in insanitary 
conditions; and  
 increasingly rapid global movements of large numbers of people for business or tourism. 
 
The need for health care systems to respond rapidly to such emergencies was one of the stimuli that 
contributed to positive support for the changes to innovation and regulatory systems outlined in 
Sections 5.2 and 5.3. 
 
5.5 Stakeholders and Advocacy Groups 
A dramatic change in overall stakeholder attitudes was seen at an early stage in the development of 
this scenario, once news of the new NHC approach to health care began to leak into the public domain. 
This fitted well with the setting up of the Patient Group Consortium that had already been set up (see 
Section 5.1). 
 
Collaboration with the ICT sector, and the speeding up of delivery of innovations through the new 
regulatory approaches, defused the “anti-big pharma” public mindset that had become such an 
important component of the first scenario. Likewise, some patient groups had become increasingly 
frustrated by the slow progress of biotechnology-related innovation, and were also becoming 
increasingly critical of the pharmaceutical MNCs.  
 
The perception that “something important was happening”, with big potential changes to a system 
seen increasingly as dysfunctional, meant that patient groups  and most members of the public who 
took an interest in such things became increasingly positive collaborators in the development of the 
new systems.  
 
This shift in public and stakeholder attitudes was a particularly important factor in facilitating the 
introduction of the new approach to Phase 3 clinical trials which required a much more active form of 
patient participation than had previously been the case.  This shift was reinforced when the relevant 
public and patient groups were brought into discussions about the implementation of the NHC 
approach, once the early, necessarily confidential negotiations had been completed. 
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The advocacy groups opposed to the development of health care systems based on advanced 
technologies had not changed their views as a result of the new developments, but the extent of their 
influence was much less than it would otherwise have been. 
 
Box 3 - Animal health: its role in the evolution of human health care systems and the bioeconomy45 
 
Animal health is considered here mainly in the context of its relationship to future human health 
scenarios, in particular zoonotic diseases. The following factors (some, such as the use of RNAi, are 
more speculative than others) relate to animal health itself and are also relevant to the evolution of the 
scenarios explored in this report. 
 
 Availability of rapid, automated disease diagnostic techniques 
 Availability of improved vaccines for use in animals 
 Non-availability of new antibiotics for use in animals due to concerns about developing resistant 
strains of bacteria 
 Limitations on the availability of existing animal-use antibiotics and anthelminthics due to 
increased resistance 
 Availability of cheap and rapid genotyping, allowing the use of genomic technologies (including 
genome-wide selection) to breed animals with increased resistance to specific diseases 
 Use of genetic modification of animals that can express RNAi to prevent multiplication of a small 
number of key infectious diseases 
 Improved and better co-ordinated management techniques for controlling the spread of infectious 
diseases 
 Decreased interest in products for animal health care by pharmaceutical multinational companies 
 Shifting of animal production to different parts of the world resulting in resurgence of familiar 
zoonotic diseases (such as Brucellosis and TB) or development of new zoonoses.   
 Introduction of existing zoonotic diseases to new parts of the world as a result of global warming 
 Potential shortages of animal protein, locally or globally, leading to weakened immune systems 
and increasing vulnerability to disease 
 The emergence of a new, serious zoonotic disease transmitted by cats or dogs posing a serious 
public health issue, given the close proximity between humans and companion animals. 
 The introduction of changes to rural farming systems in, for example, South East Asia so that 
small farmers and their families no longer live in close proximity with their pigs, chickens and other 
farm animals (these changes were imposed by governments in these countries to reduce the risk of 
zoonoses emerging from these sources and having global impacts) 
 
Future Animal Production and Health Care Systems – 2015-2030 
 
Managed Change - Optimally Developed Systems 
Animal production is organised in large industrial units of pig, poultry and some dairy production, in 
integrated production systems with food processors and supermarkets. These large units are 
surrounded by a sea of extensive production of beef, sheep and some dairy producers. This is the 
case in Northern countries and also those in the South that have the capabilities for large-scale 
intensive production (e.g. Brazil and Thailand).  
 
Management of intensive pig and poultry units is highly technically dependent. Disease control has 
been achieved by excellent biosecurity with production units segmented so that if an outbreak of 
disease is identified, individual sections of the production unit can be closed off extremely quickly. 
Rapid, automated diagnostic techniques have made it easy to detect diseases at an early stage. 
Animals have also been bred for disease resistance for a few key diseases and, due to the cheapness 
and rapidity of genotyping, genome wide selection techniques are used.   
 
                                                 
45  With thanks  to Chris Warkup (Genesis Faraday Partnership) and Professor Steve Bishop (Roslin Institute) 
for stimulating discussions 
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Whenever there is a disease outbreak, survivors are used to identify the 20,000 or so Single 
Nucleotide Polymorphisms (SNPs) that are associated with resistance to that disease. These SNPs 
are then used for subsequent selection of resistant animals.  
 
Many animals have been genetically modified to express RNAis to prevent multiplication of a small 
number of key infectious viral diseases, particularly those that are potential zoonoses. Expression of 
the RNAi is triggered by a factor in the animals’ water and this trigger can be implemented without 
humans being in contact with the animals themselves.  
 
Thus an infectious disease is identified quickly; affected animals are sealed-off from other animals; 
and a “fire-break” of genetically modified animals induced to express RNAi by a change in their water 
supply further reduces potential spread.  
 
Intensive units are carefully managed for the particular breeds and strains of animals produced so that 
the incidence of metabolic diseases is much reduced with consequential benefit for animal welfare. 
The use of much improved vaccines has also helped to control infectious diseases.  
 
Disease control in the surrounding extensive cattle and sheep units is predicated on the principle of 
living with the disease but mitigating its spread by keeping animals at low densities to reduce contact 
with other animals and by using mixed genotypes with varying resistance characteristics. The 
maintenance of this system requires high levels of skill and management and a high degree of co-
operation between units. As a result, animal production is only allowed by licence and is subject to 
planning permission to control the areas in which production may take place.  
 
One result is a pleasant countryside that is managed for aesthetic and environmental effect, except in 
areas where intensive production units are situated.  
 
Disruptive Change - Sub-optimal Systems 
 
Developing country changes 
Developing countries, particularly in Africa, continue to struggle with periodic outbreaks of serious 
disease in farm animal populations. The continual pressure for increased productivity to feed a 
burgeoning population, together with pressure on land and particularly water resources, have resulted 
in stressed animals and poor management. Together these factors have made disease outbreaks 
more likely. However, the eradication of rinderpest and the availability of better disease control 
through improved diagnostics and vaccines have meant that parts of Africa have become competitive 
with South America in terms of animal production. 
 
Health care products for animals 
The number of companies producing veterinary products has decreased due to increased competition 
and continuing difficulties in finding new candidate products. As pharmaceutical MNCs continue to 
experience problems in the innovation pipeline they have become less interested in animal health 
although most animal health products are still developed by, or in association with, these companies. 
It is no longer acceptable to use antibiotics for treatment of animals and most existing antibiotics and 
anthelminthics are no longer effective due to increasing resistance. The control of worms in sheep has 
become so difficult that all sheep production has to be in mixed farming systems carefully managed to 
control worm burdens.  
 
The livestock sector of the veterinary profession has changed its function. As improved diagnostic 
techniques have become available, vets have become less in demand to diagnose disease. Also, as 
antibiotics and other chemicals have become less available, vets are required less for treating 
disease. Instead they have become key to managing and planning for animal health and hold key 
roles in companies that produce large numbers of animals as well as co-operatives of smaller-scale 
farmers.  
 
Global Climate Change 
Global warming has resulted in serious shortages of water with large negative effects on dairy 
 47 
© OECD International Futures Programme 
production, particularly in Australia and New Zealand.  
 
A new tick borne disease has emerged in animals and has spread widely as a result of climate 
change. Unfortunately this disease can be transmitted to humans where it has serious consequences. 
Recreation in the countryside is now considered risky except in a few tick-free areas. 
 
New Zoonoses - “Man’s” best friend? 
A new zoonotic disease has emerged with a similar transmission route to foot and mouth disease. It is 
carried in farm animals but has little effect on them. However it is easily transmitted to cats and dogs 
that come into contact with farm animals. The diseases not only have serious consequences for the 
cats and dogs but these animals can also readily transmit the disease to humans where it has a high 
mortality and morbidity rate. Large numbers of pet animals are being abandoned by their owners. 
Vaccination of pets can act to control the disease to some extent but there are long waiting lists for 
vaccines. 
 
New Diseases of Farm Animals 
A new disease affecting dairy cattle has appeared and unfortunately the Holstein Friesian population 
that provides most of the world’s milk proved to be highly susceptible to this disease. The poor genetic 
diversity in the Holstein population resulted in almost all of the animals succumbing to the disease. 
There was a sudden and dramatic shortage of milk which caused not inconsiderable public 
consternation and seriously reduced the supply of milk for processing (e.g. for yoghurt and cheese). 
Milk production is now based on a much wider range of genotypes.  
 
There has been a massive increase in dairy production in China and India. However, this has allowed 
brucellosis, and in particular TB, to become major diseases of concern. A catastrophic outbreak of 
African Swine Fever in Asia has killed 95% of the pig population in affected areas. In combination with 
the increasing use of land for production of energy crop production, the result has been serious food 
shortages and consequent riots. The outbreak of a hitherto unknown enteric disease in pigs in the 
North has further disrupted the supply of pig meat. Delays in development of vaccines and 
unavailability of antibiotics have prevented effective treatment of this enteric disease.  
 
Also, the breakdown of a rationally attenuated live virus vaccine for chickens was not noticed until a 
large number of birds were affected and egg production was seriously disrupted which further reduced 
supplies of animal protein. 
 
The WTO’s Sanitary and Phytosanitary restrictions, implemented under recommendation from the 
World Organisation for Animal Health (OIE), used to control animal diseases through reduction of 
international traffic in meat and live animals. However, these restrictions have proved increasingly 
difficult to implement in a less well managed international trading environment. Diseases that were 
previously controlled have become endemic in Argentina and Brazil, resulting in shortages of meat 
production. Initially, this shortfall was compensated for by increased production in Russia and China 
but as the diseases became more widespread the tensions within the WTO increased with serious 
conflict between North and South resulting in major challenges to the regulatory structures. Many 
diseases have now become endemic worldwide.  
 
 
5.6 Interactions and Their Timing 
Achieving major change in large scale entrenched systems like the pharmaceutical industry or 
regulatory agencies has been described as “turning round an oil tanker”. However, even once you have 
turned the oil tanker round, it is still an oil tanker. The challenge in this case was equivalent to 
converting the oil tanker into a smaller, more multifunctional mother ship in charge of a fleet of 
smaller faster vessels capable of taking off in many directions while remaining well connected with 
one another.  
 
The outcome described in this scenario was dependent on a great deal of good judgement by key 
thinkers in companies and regulatory agencies backed up a considerable amount of good luck. Perhaps 
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even more than good judgement, these changes required contributors who were open minded and able 
to think creatively across disciplinary and sectoral boundaries, who had the foresight abilities to 
recognise the need for systemic change and to appreciate the advantages that would accrue to the first 
movers in making this change, and the authority (as a group) to implement the required changes.  
 
However, good luck and good judgement are not sufficient. Any number of unforeseen events, in 
addition to the lack of the right kind of talent in key players, could have prevented the necessary 
elements of the new NHC systems from coming together in the right places, in the right proportions, 
and in the right order, particularly in the early formative stages of the new initiatives.  
 
Regulators played a crucial role particularly in their willingness, primed by experience since the 
1990s, to consider innovative approaches to health care product regulation. Following closely behind 
in timing and importance, the willingness of one or two small groups of senior managers in the 
pharmaceutical industry sector to come together to discuss such issues in an open-minded environment 
was vital. And following closely behind this factor was the willingness of one or two key players in 
the ICT sector to take up the opportunity to engage in such discussions. If only one of these elements 
had been missing, the scenario described in this section would have been much less likely to emerge. 
Likewise, if one of these players had attempted to dominate the outcome, the chances of an optimal 
resolution would have been much less. 
 
5.7 Outcome for the Bioeconomy 
In the health care sector as a whole, a broader range of biotechnologies was able to contribute more 
positively to health care than in the first scenario. By 2030, the pharmaceutical company sector was 
mainly identifiable in the form of a larger number than before of companies producing commodity 
drugs. The innovative component of the health care sector could no longer be described as based on 
pharmaceuticals, far less dominated by pharmaceutical multinationals. One of the results was a wider, 
more broadly based set of products being delivered by a group of companies that had as much in 
common with the ICT industry sector as with pharmaceuticals. 
 
Through training programmes set up well before 2015, the health professionals who were the main 
market for these innovations had developed a better understanding of the demands and benefits of 
innovative health care products. They also were more willing to work collaboratively with other 
professionals at all levels in health care delivery systems, and even more important they had a positive 
approach to innovative technology. Achieving this transformation had not been easy, given the 
sometimes rigid hierarchies in the medical profession, However, it had been facilitated by the clearer 
benefits to be derived from the NHC approach, and also by the increasingly frequent arrival in their 
clinics of well informed and more demanding patients. 
 
Under this scenario, biotechnology was able to make a much more positive contribution to the health 
bioeconomy than in the first scenario, making a much wider range of contributions to health care than 
was possible with a drug-focused approach. However, the link-up with ICT companies and with a 
range of other convergent technologies meant that it was increasingly impossible to allocate particular 
advances or sources of profit solely to biotechnology. This difficulty had already been apparent in 
2007 and between then and 2030, the notion of a distinguishable separate “bioeconomy” became 
increasingly irrelevant to the reality of the economy as a whole.  
 
Nevertheless, the success of the NHC initiative and the companies it spawned in delivering health 
benefits to populations in developed and developing economies was a major influence on governments 
in continuing to provide financial support to encourage bioscience related discoveries. 
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The new NHC sector of the economy became a major source of national prosperity in those countries 
that embraced this approach and led to numerous spin-out products and initiatives in other sectors of 
the economy. 
 
There is a widely accepted expectation that an ageing population and a declining labour force will 
cause problems in developed economies - predictions are for a less healthy but longer lived population 
with a higher demand for expensive health care technologies, but a lower ability to pay for these 
through pensions, health insurance or publicly funded health services. The received wisdom is that 
demographic trends will increase the demand for biotechnology-based health care but only if the 
population has access to treatments through public health services or can afford to pay for them. 
 
An alternative projection could be that biotechnology-based innovation (along with better diets and 
more exercise) may enable the ageing population to remain fit and active (including economically 
active) for much longer than before so that the expected demand for disease treatments does not 
escalate beyond the ability of governments and individuals to satisfy it.46 This outcome would have a 
link to economic systems by placing fewer demands on health services and also on pension systems 
(“Live longer; Work longer.”). However, the societal benefits of this outcome would not be realised if 
large scale unemployment were to become a feature of these economies. 
 
The most likely outcome is a balance somewhere between these two trends – a longer-lived population 
which is less healthy and places greater demands on health services and a healthier population, living 
longer and working longer and placing fewer demands on health services. The position of this balance 
will depend on societal trends such as willingness to take control of one’s health profile through life-
style changes, and also on the nature of the biotechnology-related innovations that emerge and reach 
the market place between now and 2030. However, the “Rapid Change” scenario would appear to be 
likely to contribute to a positive societal and economic outcome along these lines. 
 
If many more people remain in active employment for a longer period than in the earlier part of the 
21st century, this could reduce the tendency for governments to worry about falling birth rates and thus 
to promote increases in birth rates because of concerns about the need to support an ageing (and 
presumed infirm) population. Over time, this acceptance of declining birth rates, and hence declining 
global populations, could have a major impact on a wider range of factors including food security, the 
use of scarce natural resources, global climate change and international conflict. 
 
6. Overview of the Scenarios 
 
The scenarios presented in Sections 4 and 5 can be seen as two sides of the same coin. On the one side 
there is the remarkable burgeoning of innovation, profit generation and customer satisfaction that is 
possible, given the right combination of circumstances and individuals. On the flip side is the situation 
that arises when an increasingly dysfunctional set of systems continues as it has always done because 
it cannot envisage a different future. 
 
Radical organisational innovation as described in the second scenario requires a particular 
combination of people and events: 
 
 key influential thinkers, senior in their organisation and able to implement change if 
necessary 
                                                 
46  Manton K.G., G.R. Lowrimore, A.D. Ullian, X. Gu and H.D. Tolley (2007), Proc. Natl. Acad. Sci. USA, 104, 
10802-10807. (Quoted in Cairncross, F. (2007) Age, Health and Wealth. Nature, 448, pp. 875-876.) 
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 representation of such thinkers from the most important categories of organisation, in this 
case multinational pharmaceutical companies and regulatory agencies in Europe and the 
United States 
 the presence of an apparently non-threatening outsider (in this case the ICT sector) with 
relevant experience to contribute the design of new types of organisation but who is not seen 
(at least initially) as a competitor for any of the organisations involved 
 a determination from the beginning that the outcomes of the discussions and negotiations will 
be implemented and a clear route to implementation  
 
The potential contribution of innovation in life sciences to the bioeconomy is enormous, but 
achieving its full potential will not be straightforward. Ideally the pharmaceutical industry sector and 
the regulatory bodies need to take part jointly and equally. Willingness to change on the part of either 
the pharmaceutical industry or the regulatory system acting alone is unlikely to have a sufficiently 
major impact on the future of the health care bioeconomy to initiate major change.  
 
This raises the point introduced at the beginning of Section 2 on the importance of the sequence of 
timing of events in achieving major change.  The changes envisaged in the “Rapid Change” scenario 
(Section 5) did not emerge from a vacuum – they depended on the existence of several developments 
that had been taking place prior to 2015, particularly in the pharmaceutical sector and regulatory 
systems. As a result of discussions initiated by regulators with the aim of speeding up drug 
development and making it simpler, mainly with the interests of pharmaceutical multinational 
companies in mind, by 2015 the regulatory systems had changed so as to make it easier and faster to 
bring a drug to market. By 2015, this had not reached the stage of enabling a SME to take a drug all 
the way through to market without any intermediation from a multinational company but it had 
opened up the field sufficiently for this to become an aspiration. This was the basis around which it 
was possible to develop the proposal for the setting up of PATC and the NHC approach and it 
demonstrates the pivotal role of regulatory systems in this process. 
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